


U.S. Department of Energy

# National Virtual Biotechnology Laboratory

Report on Rapid R&D Solutions to the COVID-19 Crisis



U.S. DEPARTMENT OF  
**ENERGY**

Office of  
Science

December 2021

U.S. Department of Energy

# National Virtual Biotechnology Laboratory

## Report on Rapid R&D Solutions to the COVID-19 Crisis

### DOE Office of Science

**Executive Oversight:** Harriet Kung, Harriet.Kung@science.doe.gov

Michelle Buchanan, Michelle.Buchanan@science.doe.gov

Ashley Predith, Ashley.Predith@science.doe.gov

### Co-Directors

Stephen Streiffer, Argonne National Laboratory

Marianne Walck, Idaho National Laboratory

### Project Leads

**Materials and Manufacturing of Critical Supplies:** Lonnie Love, Oak Ridge National Laboratory

**Molecular Design for COVID-19 Therapeutics:** Martha Head, Oak Ridge National Laboratory

**COVID-19 Testing:** Patrick Fitch, Los Alamos National Laboratory

**Epidemiological Modeling:** Budhendra Bhaduri, Oak Ridge National Laboratory

**Viral Fate and Transport:** Katrina Waters, Pacific Northwest National Laboratory




U.S. DEPARTMENT OF  
**ENERGY**

Office of  
Science

**DISCLAIMER:** This report was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government.





# Contents

Executive Summary .....	iii
1. NVBL Contributions to the COVID-19 Response: An Introduction .....	1
2. Materials and Manufacturing of Critical Supplies .....	2
3. Molecular Design for COVID-19 Therapeutics .....	6
4. COVID-19 Testing .....	9
5. Epidemiological Modeling .....	12
6. Viral Fate and Transport .....	16
7. Future Directions .....	19
Appendix A: Publications and Research Output .....	21
Appendix B: Research Team .....	25
Appendix C: Acronyms and Abbreviations .....	41



# Executive Summary

With funding from the CARES Act, the U.S. Department of Energy (DOE) established the National Virtual Biotechnology Laboratory (NVBL) in March 2020 to address key challenges associated with the COVID-19 crisis. NVBL brought together the broad scientific and technical expertise and resources of DOE's 17 national laboratories to help tackle medical supply shortages, discover potential drugs to fight the virus, develop and validate COVID-19 testing methods, model disease spread and impact across the nation, and understand virus transport in buildings and the environment. National laboratory resources leveraged for this effort include a suite of world-leading user facilities broadly available to the research community, such as light and neutron sources, nanoscale science research centers, sequencing and biocharacterization facilities, and high-performance computing facilities.

Within months, NVBL teams produced innovations in materials and advanced manufacturing that mitigated shortages in test kits and personal protective equipment (PPE), creating nearly 1,000 new jobs. They used DOE's high-performance computers and light and neutron sources to identify promising candidates for antibodies and antivirals that universities and drug companies are now evaluating. NVBL researchers also developed new diagnostic targets and sample collection approaches, and supported U.S. Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and U.S. Department of Defense (DoD) efforts to establish national guidelines used in

administering millions of tests. Researchers used artificial intelligence and high-performance computing to produce near-real-time data analysis to forecast disease transmission, stress on public health infrastructure, and economic impact, which supported decision-makers at the local, state, and national levels. NVBL teams also studied how to control indoor virus movement to minimize uptake and protect human health.

NVBL's accomplishments demonstrate not only the powerful resource represented by DOE's national laboratories working together to meet national needs, but also the effectiveness of the integrated NVBL framework for rapidly responding to emergencies with research and development (R&D) solutions. As the fight against COVID continues, sustained efforts are needed to confront this pandemic as well as future threats. Examples include:

- Establishing "supply chains on demand" to meet emergency production needs by leveraging the materials and manufacturing expertise of DOE national laboratories and developing advances in electronics, sensing, robotics, and automation capabilities.
- Improving the speed and robustness of drug discovery by integrating experimental platforms with DOE's computational and experimental user facilities, which provide unique resources to support the discovery of high-potential therapeutic agents.

- Protecting public, environmental, and animal health by developing new testing protocols and instrumentation adaptable to diverse sample types (both physiological and environmental) to quickly detect a wide range of pathogens and monitor other biorisks.
- Supporting near-real-time data needs of decision-makers at the local, regional, state, and national levels by advancing data curation, analysis, and modeling using artificial intelligence and new data science tools for managing and evaluating large diverse datasets.
- Harnessing DOE's expertise in environmental modeling to design rooms and air handling for offices, classrooms, restaurants, and other structures to minimize biorisk transmissions.

Going forward, NVBL is poised to apply the unique capabilities and expertise of the national laboratory complex to future national and international emergencies, both natural and engineered. Through this framework, the Office of Science will continue to be an integral component of agency-wide efforts to prepare for and respond to biorisks and other crises.

# NVBL Contributions to the COVID-19 Response: An Introduction

In March 2020, DOE quickly marshaled the unique expertise and resources of its national laboratories to provide R&D solutions to critical challenges posed by the global pandemic. With funding from the CARES Act, DOE established the National Virtual Biotechnology Laboratory, a consortium of 17 DOE national laboratories, each with core scientific and technical capabilities for confronting the COVID-19 crisis. These capabilities include world-leading user facilities, such as light and neutron sources, nanoscale science research centers, sequencing and biocharacterization facilities, and high-performance computing facilities, all broadly available to the research community.

As part of the NVBL framework, DOE rapidly assembled five project teams to (1) address supply chain bottlenecks by harnessing extensive additive manufacturing capabilities, (2) identify new targets for medical therapeutics, (3) develop innovations in testing capabilities, (4) provide epidemiological and logistical support, and (5) understand viral fate and transport in the environment. Each research team was charged with defining high-impact projects that could be completed in a 6-month sprint while coordinating their developments with academia, other government agencies, and the private sector.

Within months, NVBL teams produced innovations in materials and advanced manufacturing that mitigated shortages in test kits and PPE, creating nearly

1,000 new jobs. They used DOE's high-performance computers and light and neutron sources to identify promising candidates for antibodies and antivirals that universities and drug companies are now evaluating. Teams of biochemistry experts developed new diagnostic targets and sample collection approaches while supporting national guidelines used in millions of tests. NVBL researchers used state-of-the-art methods in artificial intelligence (AI) and high-performance computing to produce near-real-time data analysis to forecast disease transmission, stress on public health infrastructure, and economic impact, supporting decision-makers at the local, state, and national levels. They also studied how to control indoor virus movement to minimize uptake and protect human health.

Through its NVBL framework, DOE has contributed significantly to the nation's COVID response, demonstrating in only a few months the critical impact of its national laboratories. NVBL serves as an outstanding model for developing and sustaining capabilities to prepare for and respond to future national needs or emergencies.

The chapters that follow outline key accomplishments of NVBL's five project teams—Materials and Manufacturing of Critical Supplies, Molecular Design for COVID-19 Therapeutics, COVID-19 Testing, Epidemiological Modeling, and Viral Fate and Transport—and identify critical R&D areas essential for future biorisk preparedness.



# Materials and Manufacturing of Critical Supplies

## Objectives and Approach

**F**rom the outset of the COVID-19 pandemic, medical supply chain shortages became serious bottlenecks for frontline responders. To mitigate these shortages, 16 DOE national laboratories partnered to bring deep expertise in materials science, advanced manufacturing, and characterization capabilities to catalyze the manufacture and production scale-up of critical supplies. The NVBL Manufacturing team's efforts resulted in production of more than 10 million test kits per week (partnering with Coca-Cola and Thermo Fisher Scientific), over 3 million masks and N95 respirators per day (partnering with Cummins Filtration and DemeTech), and 250,000 nasal swabs per day by additive manufacturing. The team's accomplishments also led to the commercialization of a BioMedInnovations ventilator (which received FDA Emergency Use Authorization) and creation of two factories with over 1,000 new jobs.

To address specific supply chain bottlenecks, the Manufacturing team formed three subgroups: Personal Protection Equipment (e.g., N95 masks and face shields), Consumables (e.g., test tubes and swabs for test kits), and Ventilators. Each subgroup drew upon extensive expertise in materials science, materials characterization, manufacturing, and computation at the national laboratories to identify new approaches for producing and validating the performance of manufactured items. These activities heavily leveraged DOE user facilities, such as light and neutron sources, nanoscale science research centers, and high-performance computing facilities. In many cases, the subgroups found that the most critical component required for expanding manufacturing was the tooling required to establish a production line. With conventional tooling approaches, establishing production lines can take months. However, with advanced manufacturing methods, molds and other components



**Fig. 1.** New N95 respirator (left) produced at DemeTech factory (right). [Courtesy DemeTech]

can be produced in hours, enabling production lines to launch in a matter of weeks. In all cases, the subgroups established strategic industry partnerships for deploying developed capabilities.

## Outcomes and Impact

### *Personal Protective Equipment*


One of the first areas PPE researchers addressed was to relieve the critical shortages of N95 masks used by medical professionals. The 3M Company typically manufactures 100 million of these masks per month, far short of the demand during the COVID-19 pandemic. To help meet demand, the Carbon Fiber Technology Facility at Oak Ridge National Laboratory was converted to produce the filter media used in N95 masks. The PPE subgroup also teamed with Dr. Peter Tsia, inventor of the nonwoven filtration fabric used in N95 masks, to generate an open-source design for the charging system needed for N95 mass production. N95 filter media uses the charge placed on the fabric to capture small virus particles more effectively than simple physical filtration of the media alone. To assure their effectiveness, the produced materials

were extensively tested at DOE's light sources and nanoscale science research centers.

Additionally, the subgroup partnered with Cummins Filtration (Nashville, Tenn.) to convert an oil filter production line to one for N95 filter media, enabling production of material for over 3 million masks per day. The subgroup also partnered with DemeTech (Miami Lakes, Fla.) to convert N95 material to medical masks and N95 respirators, which received certification from the National Institute of Occupational Safety and Health in September 2020 (see Fig. 1, this page). As a result, DemeTech established a new production facility that created 600 new manufacturing jobs, and the masks are commercially available.

The PPE subgroup also partnered with DeRoyal Industries (Powell, Tenn.) to develop new capabilities for high-throughput production of face shields. The partners used extensive capabilities in metal additive manufacturing to rapidly produce metal injection molds using 3D printing (see Fig. 2a, p. 4). These molds enabled production of 40,000 new face shields per day, per machine (see Fig. 2b and c, p. 4).






**Fig. 2.** The Manufacturing team partnered with DeRoyal Industries on (a) 3D-printed tooling for (b) injection molds used to produce (c) face shields. [Courtesy Oak Ridge National Laboratory (a, b) and Getty Images (c)]

### Consumables for Test Kits

The Consumables subgroup partnered with the U.S. Department of Health and Human Services (HHS) to rapidly scale up production of consumables for test kits. These consumables included multi-well sample trays and nasal swabs (see Fig. 3, this page), along with sample collection tubes.

A critical shortage of test tubes used to collect nasal swabs emerged early in the pandemic. Working with The Coca-Cola Company, the Consumables subgroup identified bottle preforms (capped tubes that are blown with hot air into familiar drink bottles) as an excellent surrogate for these sample tubes. To evaluate the viability of using these preforms as collection tubes, the subgroup partnered with Coca-Cola (which produces 2 billion preforms per week), HHS, and five different testing companies. From this collaboration, Longhorn Therapeutics, a testing company based in Bethesda, Md., began taking delivery of 2 million preforms in April 2020.

In parallel, the subgroup designed and rapidly prototyped a mechanism to 3D print the tooling needed to mass produce the original sample collection tube by injection mold processes, working



**Fig. 3.** Mold design for (a) 96-well sample plate. (b) 3D-printed mold used to form sample plates. (c) 3D-printed swabs and (d) closeup of a printed swab tip. [Courtesy Oak Ridge National Laboratory (a, b), and Lawrence Livermore National Laboratory (c, d)]

with Thermo Fisher Scientific. In August 2020, Thermo Fisher opened a factory in Lenexa, Kan., creating more than 300 domestic medical manufacturing jobs (see Fig. 4, p. 5). In early 2021, this



**Fig. 4.** Thermo Fisher Scientific facility in Lenexa, Kan., that manufactures COVID-19 sample collection products. [Courtesy Thermo Fisher Scientific]

factory produced about 8 million test kits per week, with plans to scale to over 20 million per week.

## Ventilators

During the early phases of the pandemic, national needs required the immediate production of an additional 400,000 to 600,000 ventilators. To meet this challenge, the Ventilator subgroup focused on materials and manufacturing processes that would assist industry in rapidly accelerating the manufacture of domestically producible FDA-approved ventilator technologies. The subgroup developed a new low-cost ventilator with BioMedInnovations, LLC (Denver, N.C.) that was commercialized and approved by the FDA. This ventilator required no existing ventilator supply chain components and thus circumvented anticipated shortages for traditional components (see Fig. 5, this page).

The subgroup also performed high-fidelity modeling of human lungs to better understand ventilator control and accelerate mucus removal from the lungs. Finally, collaborating with Percussionaire (Sandpoint, Idaho), the subgroup explored



**Fig. 5.** Production-level ventilator developed with BioMedInnovations, LLC. [Courtesy BioMedInnovations, LLC]

transformative ventilation methods and developed prototype systems for next-generation Intrapulmonary Percussive Ventilation. One of these prototype developments includes a variant that replaces air with an oxygenated liquid perfluorocarbon in a process that the collaboration named Intrapulmonary Percussive Liquid Ventilation.



# Molecular Design for COVID-19 Therapeutics


## Objectives and Approach

Since the pandemic's onset, only a few medicines have received U.S. FDA Emergency Use Authorization (EUA) for directly treating COVID-19. To accelerate discovery of potential treatments and identify small molecules and antibodies that interact with key viral targets, the Molecular Design team leveraged DOE national laboratory capabilities and analytical resources in high-performance computing, AI, structural biology, and chemistry. Even with the rapid discovery and development of several vaccines (which recently received FDA approval or EUA)<sup>1</sup>, ongoing therapeutics development remains an important component of an integrated pandemic response as well as strategies to prepare for future viral challenges. To that end, the Molecular Design team continues to apply DOE capabilities to accelerate discovery of medical therapeutics targeting the virus responsible for the current pandemic—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their work has and continues to complement other public and private-sector activities.

The team has focused on identifying small molecules and antibodies that inhibit all parts of the viral life cycle. This work capitalized on an integrated computational and experimental platform established at the national laboratories and supported over time by DOE, the National Institutes of Health (NIH), DoD, Defense Advanced Research Projects Agency (DARPA), and other funding sources. The design platform's starting point includes structures of viral proteins, multiple antibody templates developed for earlier coronaviruses, and databases of chemical structures of small molecules for experimental confirmation. These inputs feed into a computational approach that combines

<sup>1</sup> DOE's light sources were accessed as part of the development process for all three COVID-19 vaccines authorized or approved for use in the United States: Pfizer-BioNTech, Moderna, and Johnson & Johnson's Janssen.





**Fig. 6.** Integrated computational and experimental platform for designing COVID-19 therapeutics. [Courtesy Oak Ridge National Laboratory]

simulation and AI methods, along with structure- and sequence-driven models, to iteratively design, make, and test new molecules. Data from experimental assays and structural characterization are then fed back into the computational methods for multiple design rounds. Platform outputs include identification of small molecules and antibodies with confirmed inhibition of a viral protein and predicted probability for good physical and safety parameters (see Fig. 6, this page). All project data will be made public, and team members are partnering with public and private organizations to further advance these discoveries along the pathway to clinical impact.

## Outcomes and Impact


### Antibody Discovery

The starting points for antibody design involved three antibodies known to bind to the spike protein of SARS-CoV-1 (the virus that caused the 2003 SARS outbreak) but *not* to the spike protein of SARS-CoV-2. The Molecular Design team's goal was to modify these existing antibody scaffolds to create new antibodies that effectively bind to and

neutralize SARS-CoV-2. The team used AI methods to sample more than  $10^{40}$  possible antibody variations, from which about 300 designed antibodies were generated and experimentally screened. Using this combined computational and experimental approach, the team identified experimentally confirmed hits for all three antibody scaffolds. All hits bind to the SARS-CoV-2 spike protein and block it from binding to the human ACE2 receptor. Additionally, some of these hits can block a pseudovirus (a harmless virus modified to include the SARS-CoV-2 spike on its surface) from entering human cells, demonstrating that these antibodies have the potential to block the first step in the infection process.

### Inhibitors of Viral Cysteine Proteases

Two viral proteases, 3 chymotrypsin-like protease (3CLpro) and papain-like protease (PLpro), are essential for SARS-CoV-2 replication and thus are important targets for pharmaceutical drug design and discovery. Both belong to the cysteine protease family, a structural family not amenable to traditional docking-based modeling pipelines, which use computational approaches to characterize and



**Fig. 7.** The Molecular Design team identified two small-molecule inhibitors for the viral proteases PLpro and 3CLpro. Shown here are the PLpro inhibitor (gray, left) and 3CLpro inhibitor (multicolor, right). [Courtesy Oak Ridge National Laboratory]

predict the atomic-level interactions of small molecules in a target protein's binding site. To identify small molecules that can inhibit the activity of these proteases, the Molecular Design team therefore needed to create an integrated, multipronged, comprehensive workflow that combined docking, molecular dynamics, and quantum mechanical simulation approaches. They used this workflow to identify, design, and optimize small-molecule protease inhibitors for both 3CLpro and PLpro that have been experimentally confirmed (see Fig. 7, this page).

The identified PLpro inhibitor binds to the PLpro protein and then reacts to form a chemical bond with its cysteine residue, which is vital for enzyme activity. In addition to the experiments confirming that the designed molecule is a potent PLpro inhibitor, further experiments have characterized the chemical reaction with cysteine and used structural biology and X-ray crystallography to reveal atomic-level details of the interaction between PLpro and the inhibitor. Moreover, partners at the University of Tennessee Health Sciences Center Regional Biocontainment Laboratory have experimentally confirmed that the designed molecule inhibits viral infection in a cell-based assay.

The 3CLpro inhibitor, identified using computational docking studies, binds to the 3CLpro protein but does not form a chemical bond with

its cysteine. An X-ray crystal structure revealed important atomic-level details of how the molecule interacts with the protein. Based on this structural information, the team used the computational workflow to design molecules with improved properties. A set of about 50 closely related molecules have been ordered for experimental testing, and the team is synthesizing and experimentally validating additional new molecules.

### *Computational Antiviral Screening*

Using the power of DOE's Leadership Computing Facilities for computational docking calculations and AI methods, the Molecular Design team computationally screened tens of millions of small molecules against more than 100 binding sites of the SARS-CoV-2 viral proteins. They also docked larger databases (on the order of 50 to 100 million molecules) against a subset of these binding sites. From these computational screens, the team acquired more than 2,000 small molecules for experimental validation in an antiviral screen. Of these molecules, 56 show some inhibition of viral infection in a cell-based assay. The team is using an independent antiviral screen to confirm the 56 hits and conducting ongoing experiments to understand which parts of the viral life cycle each confirmed hit is inhibiting.

# COVID-19 Testing

## Objectives and Approach

The beginning of the COVID-19 pandemic prompted numerous challenges to providing analytical tests for clinical and environmental virus detection and characterization. To address these challenges, NVBL formed the COVID-19 Testing team, composed of experts in genomics, biotechnology, biochemistry, nanoscience, and synthetic biology from 10 DOE national laboratories. The Testing team identified priority R&D gaps by gathering input from end-users and decision-makers and collecting first-hand experiences from several DOE national laboratories initiating in-house testing capabilities. Based on this information, the team developed an R&D roadmap to address the need to increase the availability of validated, effective, and reliable COVID-19 tests.

Key elements of the R&D roadmap were to reduce dependencies on reagents and materials for the limited approved tests by (1) identifying new diagnostic targets; (2) demonstrating new chemistries and instruments; (3) providing experimental data to support federal guideline decisions; and (4) experimentally validating new approaches for virus collection, storage, and detection. Drawing on team expertise and DOE resources, including the DOE Joint Genome Institute, the team worked to enable access to alternative testing methods and reagents to meet near-term needs while preparing for future outbreaks with new approaches and technologies. These approaches included using RNA sequence data to identify new strains and employing computer validation to rapidly evaluate diagnostic efficacy. Moreover, the team's efforts provided critical data that supported national guideline decisions used in administering millions of tests.

## Outcomes and Impact

### *Identifying New Diagnostic Targets*

The key to designing molecular detection assays for SARS-CoV-2 is identifying regions in its RNA genome that distinguish it from all other





**Fig. 8.** The nucleic acid testing process involves five phases, outlined above. [Courtesy Los Alamos National Laboratory]

viruses. The Testing team designed 78 DNA signatures from conserved regions of 41,540 SARS-CoV-2 genomes. These signatures are 60-mer in length with less than 20% probability of mapping to other viral genomes. They were incorporated into the Lawrence Livermore Microbial Detection Array (LLMDA) for detecting SARS-CoV-2 and other co-infecting pathogens and showed excellent sensitivity. The signatures can also be used in other multiplexed assays to rapidly detect SARS-CoV-2.

Using LLMDA, a technology that can detect more than 12,000 microbial species in a single test, the Testing team analyzed archived nasal pharyngeal, nose, and throat swabs to determine co-infections that could contribute to disease severity. Of all tested swabs, 91% of the COVID-19 positive samples were also positive for *Streptococcus pneumoniae* compared to 18% of COVID-19 negative samples. *Streptococcus pyogenes* was detected in 82% of the COVID-19 positive samples and 25% of the COVID-19 negative samples. Additional studies are underway to correlate other COVID-19 co-infections.

The Testing team developed several analysis tools to maintain awareness of the evolution of the SARS-CoV-2 RNA genome as it relates to nucleic acid-based assays. For example, a platform for COVID-19 genome analytics ([covid19.edgebioinformatics.org](https://covid19.edgebioinformatics.org)) offers an automatic *in silico*, or simulated, evaluation of diagnostic assays used around the world. In December


2020, this web application provided comparisons for 17 assays using 44,224 SARS-CoV-2 genomes.

Nucleic acids, such as RNA in SARS-CoV-2, are one target for diagnostic tests and are used in reverse transcription polymerase chain reaction (RT-PCR) tests. Virus proteins provide complementary targets for identification and can often be used in less expensive and simpler-to-use test formats, such as lateral flow assays. These strip tests, similar to home pregnancy test kits, require an antibody that recognizes a viral protein target. The Testing team developed an affinity reagent pipeline to screen libraries for highly specific antibodies that recognize key domains of the SARS-CoV-2 spike protein.

### **Providing Data Underpinning National Guidelines**

In an effort launched by the Diagnostics sub-group of the White House Coronavirus Task Force, the Testing team collaborated with DoD, CDC, and FDA to provide experimental data in support of national guidelines throughout all phases of the nucleic acid testing process (see Fig. 8, this page). The team's contributions included:

- Identifying and characterizing potential contamination in commercial kits.
- Evaluating sample pooling approaches to assess those with the potential to reduce per-test costs by a factor of 10.



**Fig. 9.** The COVID Whistle Breath Collector traps breath in a removable hydrogel insert for ease of testing. [Courtesy Oak Ridge National Laboratory]

- Assessing multiple viral transport media and protocols to assure test accuracy, even after less-than-desirable shipping or storage.
- Evaluating virus inactivation and extraction for test efficacy and protection of frontline health care workers.

### *Using Novel Approaches for Virus Collection and Detection*

To simplify breath collection and virus extraction, the Testing team developed a simple COVID Whistle Breath Collector with a hydrogel insert (see Fig. 9, this page). After breath is collected with the whistle, the hydrogel containing the sample can be removed for testing. The additively manufactured whistle can be readily modified to optimize collection parameters. In addition, a phone or web application can provide users with audio cues and help monitor patient variation. A university clinical partner is evaluating whistle prototypes.



**Fig. 10.** Reveal-CoV uses Reverse Transcription Loop-mediated isothermal AMPLification (RT-LAMP) to rapidly detect SARS-CoV-2. An initial inactivation step is performed at 95°C followed by amplification of the target sequence at 65°C and visual detection of color change. Total time from sample to answer is less than 1 hour. [Courtesy Lawrence Livermore National Laboratory]

The Testing team also developed the Reveal-CoV, a small, rapid nucleic acid test instrument for detecting SARS-CoV-2 (see Fig. 10, this page). The assay replaces the two step RT-PCR amplification process with a one-step amplification process called Reverse Transcription Loop-mediated isothermal AMPLification (RT-LAMP). This one-step process enables the Reveal-CoV test to provide more timely and sensitive nucleic acid detection: sample heat inactivation and lysis are performed in 5 minutes, followed by approximately 30 minutes to detect a red-to-yellow color change for a SARS-CoV-2 positive sample.


# Epidemiological Modeling

## Objectives and Approach

To assist decision-makers in understanding COVID-19 spread and impact across the nation, NVBL's Epidemiological Modeling team brought together experts in spatial demography and human dynamics research; agent-based modeling systems; and transportation, infrastructure, economic, and risk modeling. Comprising researchers from six national laboratories, the team coupled its extensive expertise with DOE's powerful supercomputers and data capabilities. Building on prior work with CDC, NIH, DoD, and the Federal Emergency Management Agency (FEMA), they created a data platform that forecasts (1) disease transmission, (2) stress on public health infrastructure, and (3) U.S. economic outlook. The following accomplishments illustrate team-developed capabilities that provided unrivaled understanding of COVID-19 impacts.

- Officials in Chicago, New York City, Illinois, New Mexico, and Tennessee, among others, used the team's data and modeling efforts to illustrate county-level trends and forecasts, pinpoint locations (such as bars and restaurants) significant to transmissions, and identify the importance of contact tracing.
- The Chicago Transit Authority and New York Metropolitan Transit Authority used the team's transportation modeling to forecast ridership under various economic reopening scenarios.
- Decision-makers at DOE, the National Nuclear Security Administration, and FEMA used results from the team's data platform, and the team shared its findings from economic impact modeling with the U.S. Bureau of Economic Analysis.
- The CDC's modeling group used the team's ensemble dashboard to visualize output data from forecast models. In addition, the CDC





**Fig. 11.** Bivariate choropleth map showing the changes in COVID-19 velocity and acceleration rates at the U.S. county level from one week in September 2020 to the next (as opposed to total number of cases). [Courtesy Oak Ridge National Laboratory]

Minority and Rural Health groups benefitted from the team's efforts to (1) identify communities most vulnerable to K-12 school reopening disruptions (including specific geographic locations); (2) determine states with high vs. low COVID burden; and (3) compare urban vs. rural COVID mobility and burden.

## Outcomes and Impact

### *Near-Real-Time Situational Awareness*

One strategy for describing the state of a public health crisis involves using a pair of easily understood values to map the conditions in a more complex region, such as a state or country, based on collective measurements from its constituent regions (e.g., counties). Using this data science approach, the Epidemiological Modeling team developed a bivariate choropleth map to simultaneously show two variables—COVID-19 velocity and acceleration rates—at the U.S. county level.

For every county, the map's 2D color legend indicates the rate at which the number of new COVID-19 cases increases over a week (velocity) and how this rate changes over that same period (acceleration). This approach to mapping velocity and acceleration provided a unique perspective on transmission dynamics and daily criticality of the COVID-19 pandemic (see Fig. 11, this page).

### *National Data Resource for Pandemic Modeling*

The unprecedented nature of the COVID-19 pandemic has highlighted the need for a data infrastructure that supports disease-tracing models with robust calibration and validation. To address this challenge, the team developed a data collection and curation platform to collect and curate disease data (600,000 data records per week for 12 weeks) on the many attributes influencing response outcomes. Compared to most public sites, the resulting NVBL platform includes far


more attributes and has created the foundation for a unique national data resource to support future epidemiological and pandemic modeling.

### *Predictive Models of COVID-19 Dynamics*

For short-term forecasts, the team developed data-driven statistical models that predict new case counts at state, county, and metropolis scales, enabling short-term planning for contact tracing staff and testing capacity needs. For long-term forecasts, the team advanced existing epidemiological modeling capabilities with platforms known as EpiGrid, EpiCast, and CityCOVID.

EpiGrid is a model of disease progression that predicts geographic spread based on classifying populations as susceptible, exposed, infectious, or recovered. It produces results at 5-km resolution that cover the entire United States. EpiCast and CityCOVID are agent-based models that simulate the actions and interactions of autonomous characters, or “agents,” following rule-based behaviors to assess their individual effects on the collective behavior of the entire system. EpiCast, originally designed to simulate community-level influenza transmission across the country, predicts COVID outcomes at the census-tract level. CityCOVID modeled hourly activities of ~3 million people across 1.2 million locations for the greater Chicago metropolitan area (see Fig. 12, this page).


Together these models perform scenario-based analysis and mitigation planning and provide local, regional, and state-level decision-makers with information on intervention effects before they are implemented. Such information includes (1) experiments to understand stay-at-home and reopening order effects and timing; (2) comparison of the impacts of bar and school reopenings on COVID spread; and (3) effects of increased holiday gatherings and interactions on COVID spread. Additionally, these models enable simulations of various vaccination protocols to forecast effects on COVID spread.



**Fig. 12.** The CityCOVID model simulates how the virus moves through populations. It generates mobility patterns based on the actions and interactions of individual people (agents). The above simulation forecasts hourly activities of 2.7 million people across 1.2 million locations in the greater Chicago metropolitan area. [Courtesy Argonne National Laboratory]

### *Resource, Economic, and Vaccination Modeling*

Using output from epidemiological models, the team calculated demand for practitioner types as well as committed and consumable resources for each U.S. county in multiple scenarios. They also applied models to forecast COVID-19 economic impact under multiple scenarios for virus progression and to estimate the cumulative economic impacts of shutdowns and potential recovery strategies. In addition, the team developed a new epidemiological modeling approach to quantify contact tracing, testing, and vaccination strategies in resource-constrained environments and to help



**Fig. 13.** Cellular phone-based movement data provided assessment of social gatherings and explained consequent changes in COVID cases. For example, this data helped explain and validate a sixfold increase in COVID cases in Sturgis, S.D. (inside the red circle) following an August 2020 motorcycle rally. [Courtesy Oak Ridge National Laboratory]

identify optimal vaccination strategies for states and large metropolitan areas.

### *Mobility Modeling*

Team members developed approaches to assess mobility behavior changes, for personal and freight movements, in response to SARS-CoV-2 and variants across the United States. Analysis of commercial vehicle and cellular phone-derived mobility data revealed travel patterns for commercial activity by type and across industries, including bars and restaurants as well as passenger, fleet, and heavy-duty vehicles (see Fig. 13, this page). Three different agent-based transportation modeling and simulation systems—POLARIS, BEAM, and CommuterSim—provided scenario-based transportation analysis. Scenarios were developed and assessed for the greater Chicago and New York City areas, with emphasis on public transit impact. The models provided ridership forecasts

for various degrees of economic reopening with aversion to shared mobility such as public transit.

### *COVID-19 Data and Visualization Platform*

The Epidemiological Modeling team developed a comprehensive data access and visualization platform that can process multimodal and multisource data, enabling informed decision-making and monitoring of potential recovery efforts. In addition to showing current infection spread, the platform also captures the impact of human dynamics on disease spread and location and the availability of critical infrastructure. The platform can support epidemiological and pandemic modeling and simulations driven by high-performance computing, and it is extensible, allowing third-party integration and services to use the curated data and analytics in near-real time.




# Viral Fate and Transport

## Objectives and Approach

**S**ARS-CoV-2 is thought to be passed principally between people through inhalation of expelled droplets and aerosolized particles, but transmission through contact with contaminated surfaces remains a concern under certain circumstances. Data suggest aerosolized SARS-CoV-2 can persist in enclosed environments (especially in poorly ventilated spaces) for several hours, and the virus can persist on some surfaces for days. A lack of understanding of SARS-CoV-2 transport and fate and associated particles in the environment, including air, water, and surfaces, limits the ability to devise strategies to reduce virus uptake and prevent infection. Controlling community and workplace spread requires understanding the factors regulating SARS-CoV-2 viability, transmission, and transport as well as virus prevalence in the environment.

To better understand these factors, the Viral Fate and Transport team mobilized researchers across 11 DOE national laboratories and combined unique experimental facilities with physics-based, data-driven modeling and simulation to study SARS-CoV-2 transmission, transport, and fate. The resulting information has provided key insights required to understand factors involved in emergence, circulation, and resurgence of pathogenic microbes and to support pandemic response. The team focused on understanding and ultimately predicting SARS-CoV-2 viability in varied environments, with the goal of rapidly informing strategies that guide the nation's return to normal activities. Primary team objectives included (1) prioritizing administrative and engineering controls that reduce the risk of SARS-CoV-2 transmission within an enclosed environment, (2) identifying the chemical and physical properties that influence SARS-CoV-2 binding to common surfaces, and (3) understanding the contribution of environmental reservoirs and conditions to SARS-CoV-2 transmission and resurgence.



**Fig. 14.** (a) Computational fluid dynamic simulation of the airflow and distribution of expelled respiratory particles within a classroom or office configuration. (b) Experimental setup to measure particle distribution in a classroom or office configuration. [Courtesy Sandia National Laboratories (a) and Lawrence Berkeley National Laboratory (b)]

## Outcomes and Impact


### *Airborne Viral Transport and Fate Indoors*

Leveraging highly instrumented, configurable facilities and computational capabilities available at DOE national laboratories, the Viral Fate and Transport team uncovered robust and quantitative information about how behavioral, environmental, and operational conditions affect airborne transmission risk. For example, the team used computational fluid dynamic models to learn about airborne virus transport and how to reduce risk of indoor transmission in spaces like classrooms and conference rooms. Simulations are based on experimental results obtained using carbon dioxide gas and different particle sizes released in a manner mimicking respiratory gas and fluid emissions into the air (see Fig. 14, this page).

### *Surface Chemistry and Material Science Solutions*

The Viral Fate and Transport team designed new antiviral materials with low potential toxicity to humans. One class of materials is based on composites of a transition metal oxide (component A) combined with a copper-based virucidal agent (component B) that can adsorb SARS-CoV-2, trapping it in a thin film on the material's surface

and thereby deactivating it. When tested individually, the A and B components demonstrate little to no virucidal properties, but their combination, A x B, produces strong antiviral activity against SARS-CoV-2 (see Fig. 15, this page). This research examined binding of surrogate virus systems, as well as the SARS-CoV-2 spike protein, to nonbiological surfaces. Supporting this research, the team also conducted direct imaging of virus-surface interactions using a range of imaging techniques available at DOE scientific user facilities.



**Fig. 15.** Antiviral activities of studied material systems vs. pure constituents (A) and (B) are shown in the graph. The image at right, taken using energy-dispersive X-ray spectroscopy (STEM-EDS), illustrates distribution of the materials (A, green) and (B, blue) on the surface of the developed composite antiviral materials (A)x(B). [Courtesy Ames Laboratory and Iowa State University]



### *Viral Transport and Emergence from Environmental Reservoirs*

The Viral Fate and Transport Team analyzed data-sets to produce validated models for SARS-CoV-2 fate and transport in wastewater and groundwater. Scenarios of particular interest were sewer water or septic tank seepage into groundwater and associated subsurface transport, potential exposure routes, and risks to the population. The team also determined the effects of climate conditions on viral environmental transport and compared viral DNA sequences from wastewater and groundwater

sites to analyze SARS-CoV-2 fate and infectivity associated with genomic change. The primary result from both groundwater and wastewater modeling is development of 1D and 3D models using literature data for other viruses. Important transport-related model parameters are advection, diffusion, colloid facilitated processes, adsorption/desorption, and inactivation. Scenarios run with these parameters show that in unconsolidated subsurface environments, 200 m from origin, viral concentrations are 10% of the concentration found at the source.

# Future Directions

DOE's National Virtual Biotechnology Laboratory has proven to be an exceptionally effective contributor to the nation's COVID-19 response. NVBL accomplishments demonstrate not only the game-changing resource represented by DOE's 17 national laboratories working together to meet national needs, but also the framework's effectiveness in rapidly responding to emergencies with R&D solutions. Because the COVID-19 fight is far from over, a continuing, sustained effort is needed to meet pandemic challenges, as well as future natural or manmade biorisks. The NVBL framework can effectively integrate the project areas described in this document, as well as define new projects to support scalable biosurveillance and prediction capabilities. The following sections outline major R&D areas essential to preparing for future national threats and challenges.

## Materials and Manufacturing of Critical Supplies

DOE's extensive expertise and capabilities in materials and manufacturing are critical to the discovery of new materials important in fighting infectious agents. New fabric that combines improved filtering and antimicrobial or antiviral agents is necessary for reducing the volume of face masks or other essential PPE. Moreover, new materials are needed to improve the ability to sterilize and reuse consumables. The supply chain shortages experienced early in the COVID-19 pandemic revealed the need for advanced manufacturing

approaches for rapid tooling to enable industries to pivot quickly and ramp up supply production. Also required are capabilities to rapidly and resiliently establish supply chains to meet emergency needs (i.e., "supply chains on demand"). The COVID crisis also demonstrated major bottlenecks in assembly processes. Although parts could be mass produced during the pandemic, assembly lagged, illustrating the need for new electronics, sensing, robotics, and automation capabilities to facilitate rapid assembly.

## Molecular Design for Medical Therapeutics

NVBL made major advances in not only understanding the structure and function of biological threats, but also in supporting the development of molecular therapeutics for COVID-19 and other biorisks. Underpinning these achievements are the unparalleled capabilities of DOE's high-performance Leadership Computing Facilities, combined with structural biology studies at its light, neutron, and nanoscale science research center user facilities. However, the job is not finished. New computational approaches are needed to improve the rapid screening of millions of test molecules against virus and bacterial targets to quickly converge on high-potential therapeutic agents. Integrating these computational tools with experimental platforms available at DOE user facilities would vastly improve the robustness of effective drug selection.



## Pathogen Testing

Future protection of public, environmental, and animal health through rapid detection and monitoring of viral and bacterial agents requires fast, patient-friendly, and cost-effective testing protocols along with new types of instrumentation. Such testing approaches are needed to address the evolution of the SARS-CoV-2 virus (or other viruses or bacteria) and provide early warning of future pandemics. These new tests should be adaptable to a range of sample types—both physiological (nasal, saliva, blood, urine, and feces) and environmental (air, surfaces, and wastewater or groundwater). Advanced testing approaches that use multiple pathogen and host-response signatures to detect a wide array of pathogens are needed to, for example, understand the role of co-infections in patient outcomes.

## Epidemiological Modeling

The COVID-19 pandemic underscored the challenge of managing huge amounts of data to support decisions at the local, regional, state, and national levels. Advances are needed to integrate data from new physiological and environmental tests with myriad other types of monitored data. Also, a new framework is needed for data curation, analysis, and modeling that will respond to the near-real-time requirements of decision-makers during public health emergencies. Such a framework could foster epidemic surveillance through development of a critically needed national public health data and reporting standard. Further, new data science and advanced AI approaches to bio-surveillance and data fusion are needed to evaluate diverse mobility and demographic datasets. These approaches could be used to generate not only “early warning” alerts, but also impactful model-derived assessments of outbreak potential. DOE’s scalable data and high-performance computing capabilities would enable the synthesis of dynamic, accurate, and multimodal operations frameworks to parameterize epidemiological models on human

mobility and interactions. Such an approach would (1) greatly improve both the accuracy and granularity of predictive epidemiological models; (2) reduce uncertainties associated with prior approaches to contact network simulation; and (3) establish a modeling approach to rapidly quantify contact tracing, testing, and vaccination strategies in resource-constrained environments. These frameworks would also serve as essential tools to help identify optimal vaccination strategies for states and large metropolitan areas.

## Viral Fate and Transport

Designing engineered solutions that mitigate disease spread requires enhanced understanding of how infecting agents are transported in the environment, both indoors and outdoors in air and water sources. DOE’s expertise in building technologies and computational modeling can provide the knowledge needed to effectively design rooms and air handling for offices, classrooms, restaurants, and other structures to minimize biohazard transmission. In addition, DOE’s vast experience in understanding contaminant transport in the environment can reveal how viruses and bacteria are spread in these settings.

## Conclusion

Through the integrated NVBL framework, DOE has demonstrated the power of bringing together the unique expertise and capabilities of its national laboratories to meet the challenges of an international pandemic. Since March 2020, NVBL advancements in manufacturing, therapeutics, testing, modeling, and viral fate and transport have illuminated the importance of essential, effective R&D in bioemergency preparedness and response. Going forward, NVBL can serve as a critical component of DOE’s integrated response to future biorisks and other emergencies, both natural and engineered.



## Appendix A

# Publications and Research Output

The following list represents publications as of December 2021 and does not include manuscripts in preparation or review.

## Chapter 2: Materials and Manufacturing of Critical Supplies

### Publications

DeAngelis, H. E.; Grillet, A. M.; Nemer, M. B.; Wasiolek, M. A.; Hanson, D. J.; Omana, M. A.; Sanchez, A. L.; Vehar, D. W.; Thelen, P. M. Gamma Radiation Sterilization of N95 Respirators Leads to Decreased Respirator Performance. *PLoS One* **2021**, 16 (4), e0248859. DOI: 10.1371/journal.pone.0248859

Larsen, G. S.; Cheng, Y.; Daemen, L. L.; Lamichhane, T. N.; Hensley, D. K.; Hong, K.; Meyer, H. M.; Monaco, S. J.; Levine, A. M.; Lee, R. J.; Betters, E.; Sitzlar, K.; Heineman, J.; West, J.; Lloyd, P.; Kunc, V.; Love, L.; Theodore, M.; Paranthaman, M. P. Polymer, Additives, and Processing Effects on N95 Filter Performance. *ACS Appl. Polym. Mater.* **2021**, 3 (2), 1022–1031. DOI: 10.1021/acsapm.0c01294

Nikitin, V.; Andrade, V. D.; Slyamov, A.; Gould, B. J.; Zhang, Y.; Sampathkumar, V.; Kasthuri, N.; Gürsoy, D.; De Carlo, D. Distributed Optimization for Nonrigid Nano-Tomography. *IEEE Transactions on Computational Imaging* **2021**, 7, 272–287. DOI: 10.1109/TCI.2021.3060915

Wang, P. L.; Roschli, A.; Paranthaman, M. P.; Theodore, M.; Cramer, C. L.; Zangmeister, C.; Zhang, Y.; Urban, J. J.; Love, L. Recent Developments in Filtration Media and Respirator Technology in Response to COVID-19. *MRS Bull.* **2021**, 46, 822–831. DOI: 10.1557/s43577-021-00173-6

### Patents

Zhang, Y.; Powers, D. J.; Pupek, K. Z.; Hryn, J. N.; Krumdick, G. K.; Chaudhuri, S. Nanofiber Filter Medium for Reusable Facemask and Filtering Facepiece Respirator. ANL IN-20-055.

## Chapter 3: Molecular Design for COVID-19 Therapeutics

### Publications

Bhati, A. P.; Wan, S.; Alfè, D.; Clyde, A. R.; Bode, M.; Tan, L.; Titov, M.; Merzky, A.; Turilli, M.; Jha, S.; Highfield, R. R.; Rocchia, W.; Scafuri, N.; Succi, S.; Kranzlmüller, D.; Mathias, G.; Wifling, D.; Donon, Y.; Di Meglio, A.; Vallecorsa, S.; Ma, H.; Trifan, A.; Ramanathan, A.; Brettin, T.; Partin, A.; Xia, F.; Duan, X.; Stevens, R.; Coveney, P. V. Pandemic Drugs at Pandemic Speed: Infrastructure for Accelerating COVID-19 Drug Discovery with Hybrid Machine Learning- and Physics-Based Simulations on High Performance Computers. *Interface Focus* **2021**, 11 (6), 20210018. DOI: 10.1098/rsfs.2021.0018

Chai, J.; Cai, Y.; Pang, C.; Wang, L.; McSweeney, S.; Shanklin, J.; Liu, Q. Structural Basis for SARS-CoV-2 Envelope Protein Recognition of Human Cell Junction Protein PALS1. *Nat. Commun.* **2021**, 12 (1), 3433. DOI: 10.1038/s41467-021-23533-x

Clyde, A.; Galanie, S.; Kneller, D. W.; Ma, H.; Babuji, Y.; Blaiszik, B.; Brace, A.; Brettin, T.; Chard, K.; Chard, R.; Coates, L.; Foster, I.; Hauner, D.; Kertesz, V.; Kumar, N.; Lee, H.; Li, Z.; Merzky, A.; Schmidt, J. G.; Tan, L.; Titov, M.; Trifan, A.; Turilli, M.; Van Dam, H.; Chennubhotla, S. C.; Jha, S.; Kovalevsky, A.; Ramanathan, A.; Head, M. S.; Stevens, R. High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor. *J. Chem. Inf. Model.* **2021**. DOI: 10.1021/acs.jcim.1c00851 (accessed 2021-12-07).

Joshi, R. P.; Gebauer, N. W. A.; Bontha, M.; Khazaieli, M.; James, R. M.; Brown, B.; Kumar, N. 3D-Scaffold: Deep Learning Framework to Generate 3D Coordinates of Drug-like Molecules with Desired Scaffolds. *J. Phys. Chem. B* **2021**, 125 (44), 12166–12176. DOI: 10.1021/acs.jpcb.1c06437

Kneller, D. W.; Li, H.; Galanie, S.; Phillips, G.; Labbé, A.; Weiss, K. L.; Zhang, Q.; Arnould, M. A.; Clyde, A.; Ma, H.; Ramanathan, A.; Jonsson, C. B.; Head, M. S.; Coates, L.; Louis, J. M.; Bonnesen, P. V.; Kovalevsky, A. Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. *J. Med. Chem.* **2021**. DOI: 10.1021/acs.jmedchem.1c01475 (accessed 2021-12-07).



Koenig, P.-A.; Das, H.; Liu, H.; Kümmerer, B. M.; Gohr, F. N.; Jenster, L.-M.; Schiffelers, L. D. J.; Tesfamariam, Y. M.; Uchima, M.; Wuerth, J. D.; Gatterdam, K.; Ruetalo, N.; Christensen, M. H.; Fandrey, C. I.; Normann, S.; Tödtmann, J. M. P.; Pritzl, S.; Hanke, L.; Boos, J.; Yuan, M.; Zhu, X.; Schmid-Burgk, J. L.; Kato, H.; Schindler, M.; Wilson, I. A.; Geyer, M.; Ludwig, K. U.; Hällberg, B. M.; Wu, N. C.; Schmidt, F. I. Structure-Guided Multivalent Nanobodies Block SARS-CoV-2 Infection and Suppress Mutational Escape. *Science* **2021**, 371 (6530), eabe6230. DOI: 10.1126/science.abe6230

Lee, H.; Merzky, A.; Tan, L.; Titov, M.; Turilli, M.; Alfe, D.; Bhati, A.; Brace, A.; Clyde, A.; Coveney, P.; Ma, H.; Ramanathan, A.; Stevens, R.; Trifan, A.; Van Dam, H.; Wan, S.; Wilkinson, S.; Jha, S. Scalable HPC and AI Infrastructure for COVID-19 Therapeutics. In *PASC '21: Proceedings of the Platform for Advanced Scientific Computing Conference*, Geneva, Switzerland, 2021; Association for Computing Machinery: New York, NY, USA, **2021**; Article 2, pp 1–13. DOI: 10.1145/3468267.3470573

Merzky, A. T. M.; Titov, M.; Saadi, A. A.; Jha, S. Design and Performance Characterization of RADICAL-Pilot on Leadership-Class Platforms. *IEEE Transactions on Parallel and Distributed Systems* **2022**, 33 (4), 818–829. DOI: 10.1109/TPDS.2021.3105994

Reese, J. T.; Unni, D.; Callahan, T. J.; Cappelletti, L.; Ravanmehr, V.; Carbon, S.; Shefchek, K. A.; Good, B. M.; Balhoff, J. P.; Fontana, T.; Blau, H.; Matentzoglou, N.; Harris, N. L.; Munoz-Torres, M. C.; Haendel, M. A.; Robinson, P. N.; Joachimiak, M. P.; Mungall, C. J. KG-COVID-19: A Framework to Produce Customized Knowledge Graphs for COVID-19 Response. *Patterns* **2021**, 2 (1), 100155. DOI: 10.1016/j.patter.2020.100155

Saadi, A. A.; Alfe, D.; Babuji, Y.; Bhati, A.; Blaiszik, B.; Brace, A.; Brettin, T.; Chard, K.; Chard, R.; Clyde, A.; Coveney, P.; Foster, I.; Gibbs, T.; Jha, S.; Keipert, K.; Kranzlmüller, D.; Kurth, T.; Lee, H.; Li, Z.; Ma, H.; Mathias, G.; Merzky, A.; Partin, A.; Ramanathan, A.; Shah, A.; Stern, A.; Stevens, R.; Tan, L.; Titov, Trifan, A.; M.; Tsaris, A.; Turilli, M.; Van Dam, H.; Wan, S.; Wifling, D.; Yin, J. IMPECCABLE: Integrated Modeling Pipeline for COVID Cure by Assessing Better LEads. In *ICPP 2021: Proceedings of the 50th International Conference on Parallel Processing*, Chicago, IL, USA, 2021; Association for Computing Machinery: New York, NY, USA, **2021**; Article 40, pp 1–12. DOI: 10.1145/3472456.3473524

Stefan, M. A.; Light, Y. K.; Schwedler, J. L.; McIlroy, P. R.; Courtney, C. M.; Saada, E. A.; Thatcher, C. E.; Phillips, A. M.; Bourguet, F. A.; Mageeney, C. M.; McCloy, S. A.; Collette, N. M.; Negrete, O. A.; Schoeniger, J. S.; Weilhammer, D. R.; Harmon, B. Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies. *mAbs* **2021**, 13 (1), 1958663. DOI: 10.1080/19420862.2021.1958663

Zhang, K.; Zheludev, I. N.; Hagey, R. J.; Haslecker, R.; Hou, Y. J.; Kretsch, R.; Pintilie, G. D.; Rangan, R.; Kladwang, W.; Li, S.; Wu, M. T.-P.; Pham, E. A.; Bernardin-Souibgui, C.; Baric, R. S.; Sheahan, T. P.; D'Souza, V.; Glenn, J. S.; Chiu, W.; Das, R. Cryo-EM and Antisense Targeting of the 28-kDa Frameshift Stimulation Element from the SARS-CoV-2 RNA Genome. *Nat. Struct. Mol. Biol.* **2021**, 28 (9), 747–754. DOI: 10.1038/s41594-021-00653-y

## Chapter 4: COVID-19 Testing

### Publications

Hodge, C. D.; Rosenberg, D. J.; Grob, P.; Wilamowski, M.; Joachimiak, A.; Hura, G. L.; Hammel, M. Rigid Monoclonal Antibodies Improve Detection of SARS-CoV-2 Nucleocapsid Protein. *mAbs* **2021**, 13 (1), 1905978. DOI: 10.1080/19420862.2021.1905978

Jha, R. K.; Yankey, A.; Shabazz, K.; Naranjo, L.; Shin, S.-M.; Velappan, N.; Bradbury, A. R. M.; Strauss, C. E. M. Engineered pH-Sensitive Protein G/IgG Interaction. *ACS Chem. Biol.* **2021**, 16 (7), 1142–1146. DOI: 10.1021/acscchembio.0c00943

Kim, Y.; Wower, J.; Maltseva, N.; Chang, C.; Jedrzejczak, R.; Wilamowski, M.; Kang, S.; Nicolaescu, V.; Randall, G.; Michalska, K.; Joachimiak, A. Tipiracil Binds to Uridine Site and Inhibits Nsp15 Endoribonuclease NendoU from SARS-CoV-2. *Commun. Biol.* **2021**, No. 4, 193. DOI: 10.1038/s42003-021-01735-9 (Article in collection "Advances in SARS-CoV-2 Biology".)

Kneller, D. W.; Galanie, S.; Phillips, G.; O'Neill, H. M.; Coates, L.; Kovalevsky, A. Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals. *Structure* **2020**, 28 (12), 1313–1320.e3. DOI: 10.1016/j.str.2020.10.007

Kneller, D. W.; Phillips, G.; Kovalevsky, A.; Coates, L. Room-Temperature Neutron and X-ray Data Collection of 3CL M(pro) from SARS-CoV-2. *Acta Crystallogr., Sect. F: Struct. Biol. Commun.* **2020**, 76 (Pt. 10), 483–487. DOI: 10.1107/S2053230X20011814

Kneller, D. W.; Phillips, G.; O'Neill, H. M.; Tan, K.; Joachimiak, A.; Coates, L.; Kovalevsky, A. Room-Temperature X-ray Crystallography Reveals the Oxidation and Reactivity of Cysteine Residues in SARS-CoV-2 3CL M(pro): Insights into Enzyme Mechanism and Drug Design. *IUCrJ* **2020**, 7 (Pt. 6), 1028–1035. DOI: 10.1107/S2052252520012634

Kneller, D. W.; Phillips, G.; Weiss, K. L.; Pant, S.; Zhang, Q.; O'Neill, H. M.; Coates, L.; Kovalevsky, A. Unusual Zwitterionic Catalytic Site of SARS-CoV-2 Main Protease Revealed by Neutron Crystallography. *J. Biol. Chem.* **2020**, 295 (50), 17365–17373. DOI: 10.1074/jbc.AC120.016154

Moehling, T. J.; Choi, G.; Dugan, L. C.; Salit, M.; Meagher, R. J. LAMP Diagnostics at the Point-of-Care: Emerging Trends and Perspectives for the Developer Community. *Expert Rev. of Mol. Diagn.* **2021**, 21 (1), 43–61. DOI: 10.1080/14737159.2021.1873769

Ngo, V. A.; Jha, R. K. Identifying Key Determinants and Dynamics of SARS-CoV-2/ACE2 Tight Interaction. *PLoS One* **2021**, 16 (11), e0259705. DOI: 10.1371/journal.pone.0259705

Omberg, K.; Engelmann, Hutchison, J.; Melville, A.; Oxford, K.; Victry, K. Evaluation of Three Extraction Kits with a 2019-nCoV Assay, PNNL-3008. **2020**. DOI: 10.2172/1833861

Ospiuk, J.; Azizi, S.-A.; Dvorkin, S.; Endres, M.; Jedrzejczak, R.; Jones, K. A.; Kang, S.; Kathayat, R. S.; Kim, Y.; Lisnyak, V. G.; Maki, S. L.; Nicolaescu, V.; Taylor, C. A.; Tesar, C.; Zhang, Y.-A.; Zhou, Z.; Randall, G.; Michalska, K.; Snyder, S. A.; Dickinson, B. C.; Joachimiak, A. Structure of Papain-Like Protease from SARS-CoV-2 and Its Complexes with Non-Covalent Inhibitors. *Nat. Commun.* **2021**, *12* (1), 743. DOI: 10.1038/s41467-021-21060-3

Wilamowski, M.; Hammel, M.; Leite, W.; Zhang, Q.; Kim, Y.; Weiss, K. L.; Jedrzejczak, R.; Rosenberg, D. J.; Fan, Y.; Wower, J.; Bierma, J. C.; Sarker, A. H.; Tsutakawa, S. E.; Pingali, S. V.; O'Neill, H. M.; Joachimiak, A.; Hura, G. L. Transient and Stabilized Complexes of Nsp7, Nsp8, and Nsp12 in SARS-CoV-2 Replication. *Biophys. J.* **2021**, *120* (15), 3152–3165. DOI: 10.1016/j.bpj.2021.06.006

Wilamowski, M.; Sherrell, D. A.; Minasov, G.; Kim, Y.; Shuvalova, L.; Lavens, A.; Chard, R.; Maltseva, N.; Jedrzejczak, R.; Rosas-Lemus, M.; Saint, N.; Foster, I. T.; Michalska, K.; Satchell, K. J. F.; Joachimiak, A. 2'-O Methylation of RNA Cap in SARS-CoV-2 Captured by Serial Crystallography. *Proc. Natl. Acad. Sci. U. S. A.* **2021**, *118* (21), e2100170118. DOI: 10.1073/pnas.2100170118

## Patents and Invention Disclosures

Non-provisional patent filed 15639: Highly Effective SARS-CoV-2 Neutralizing Humanized Nanobodies.

Provisional patent for entire suite of 18 antibodies. EIDR S133918.

Joint invention disclosure submitted for COVID Whistle.

## Chapter 5: Epidemiological Modeling

### Publications

Beyeler, W.; Acquesta, E.; Klise, K.; Makvandi, M.; Finley, P. *Adaptive Recovery Model: Designing Systems for Testing, Tracing, and Vaccination to Support COVID-19 Recovery Planning*; SAND2020-11014; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1684646

Beyeler, W.; Frazier, C.; Krofcheck, D.; Swiler, L. P.; Portone, T.; Klise, K. *Uncertainty Analysis Framework for the Hospital Resource Supply Model for COVID-19*; SAND2020-5569; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1763544

Blonigan, P.; Ray, J.; Safta, C. Forecasting Multi-Wave Epidemics Through Bayesian Inference. *Arch. Computat. Methods Eng.* **2021**, *28*, 4169–4183. DOI: 10.1007/s11831-021-09603-9

Castro, L. A.; Shelley, C. D.; Osthus, D.; Michaud, I.; Mitchell, J.; Manore, C. A.; Del Valle, S. Y. How New Mexico Leveraged a COVID-19 Case Forecasting Model to Preemptively Address the Health Care Needs of the State: Quantitative Analysis. *JMIR Public Health Surveill.* **2021**, *7* (6), e27888. DOI: 10.2196/27888

Fair, J. M.; LeClaire, R. J.; Dauelsberg, L. R.; Ewers, M.; Pasqualini, D.; Cleland, T.; Rosenberger, W. Systems Dynamics and the Uncertainties of Diagnostics, Testing and Contact Tracing for COVID-19. *Methods* **2021**, *195*, 77–91. DOI: 10.1016/j.jymeth.2021.03.008

Frazier, C. R.; Krofcheck, D. J.; Gearhart, J. L.; Beyeler, W. E. *Integrated Resource Supply-Demand-Routing Model for the COVID-19 Crisis*; SAN D2020-5277; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1763531

Kaligotla, C.; Ozik, J.; Collier, N. T.; Macal, C. M.; Stevens, A.; Mucenic, B.; Hutton, A.; Choe, K. Development of Large-Scale Synthetic Population to Simulate COVID-19 Transmission and Response. In *Proceedings of the 2020 Winter Simulation Conference*, Virtual, December 14–8, 2020; Bae, K.-H., Feng, B., Kim, S., Lazarova-Molnar, S., Zheng, Z., Roeder, T., Thiesing, R., Eds. 2020. <https://informatics-sim.org/wsc20papers/088.pdf> (accessed 2021-11-16).

Klise, K. A.; Bynum, M. L. *Facility Location Optimization Model for COVID-19 Resources*; SAND-2020-4693R; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1617839

Klise, K.; Beyeler, W.; Finley, P.; Makvandi, M. Analysis of Mobility Data to Build Contact Networks for COVID-19. *PLoS One* **2021**, *16* (4), e0249726. DOI: 10.1371/journal.pone.0249726

Lin, Y. T.; Neumann, J.; Miller, E.; Posner, R.; Mallela, A.; Safta, C.; Ray, J.; Thakur, G.; Chinthavali, S.; Hlavacek, W. Daily Forecasting of Regional Epidemics of Coronavirus Disease with Bayesian Uncertainty Quantification, United States. *Emerging Infect. Dis.* **2021**, *27* (3), 767–778. DOI: 10.3201/eid2703.203364

Macal, C. M.; Ozik, J.; Collier, N. T.; Kaligotla, C.; MacDonell, M. M.; Wang, C.; LePoire, D. J.; Chang, Y.-S.; Martinez-Moyano, I. J. CityCOVID: A Computer Simulation of COVID-19 Spread in a Large-Urban Area. In *Proceedings of the 2020 Winter Simulation Conference*, Virtual, December 14–8, 2020; Bae, K.-H., Feng, B., Kim, S., Lazarova-Molnar, S., Zheng, Z., Roeder, T., Thiesing, R., Eds. 2020. <https://informatics-sim.org/wsc20papers/087.pdf> (accessed 2021-11-16).

Makvandi, M.; Wallis, L. D.; West, C. N.; DeAngelis, H. E.; VanWinkle, Z.; Halkjaer-Knudsen, V.; Acquesta, E.; Beyeler, W. E.; Klise, K. A.; Finley, P. D. *Modeling Efficient and Equitable Distribution of COVID-19 Vaccines*; SAND2020-11973; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1718986

Martinez, C.; Jones, J. E.; Levin, D.; Trask, N. A.; Finley, P. D. *Physics-Informed Machine Learning for Epidemiological Models*; SAND2020-11933R; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1706217

Ozik, J.; Wozniak, J. M.; Collier, N.; Macal, C. M.; Binois, M. A Population Data-Driven Workflow for COVID-19 Modeling and Learning. *The International Journal of High Performance Computing Applications* **2021**, *35* (5), 483–499. DOI: 10.1177/10943420211035164

Piburn, J.; Kaufman, J.; Sorokine, A.; Axley, E. *DOE COVID-19 Data Curation Effort: An Initial Analysis of the Data*; Oak Ridge National Laboratory: Oak Ridge, TN, 2020.

Reinicke, N.; Borlaug, B.; Moniot, M. *Changes in When and Where People are Spending Time in Response to COVID-19*; NREL/TP-5400-78473; National Renewable Energy Laboratory: Golden, CO, 2021. DOI: 10.2172/1808276

Swiler, L.; Portone, T.; and Beyeler, W. *Uncertainty Analysis of Hospital Resource Demand Model for COVID-19*; SAND2020-4900; Sandia National Laboratories: Albuquerque, NM, 2020. DOI: 10.2172/1630395



## Software Disclosures

Argonne National Laboratory. *The Chicago Social Interaction Model (ChiSIM) Framework*. Revision 0.3 for chi\_sim, Ver. 0.4.2; <https://github.com/Repast/chiSim> (accessed 2021-11-16).

Argonne National Laboratory. *CityCOVID*. SF-21-101. September 13, 2021.

Argonne National Laboratory. *Repast for High-Performance Computing (RepastHPC)*. Ver. 2.3.1. <https://github.com/Repast/repast.hpc> (accessed 2021-11-16).

Sandia National Laboratories. PRIME. Ver. 1. <https://sandialabs.github.io/PRIME/> (accessed 2021-12-01).

## Chapter 6: Viral Fate and Transport

### Publications

Bueno de Mesquita, P. J.; Delp, W. W.; Chan, W. R.; Bahnfleth, W. P.; Singer, B. C. Control of Airborne Infectious Disease in Buildings: Evidence and Research Priorities. *Indoor Air* **2021**. DOI: 10.1111/ina.12965

Chien, C. H.; Cheng, M. D.; Im, P.; Nawaz, K.; Fricke, B.; Armstrong, A. Characterization of the Indoor Far-Field Aerosol Transmission in a Model Commercial Office Building. *Int. Commun. Heat Mass Transfer* **2021**, 105744. DOI: 10.1016/j.icheatmasstransfer.2021.105744

Chien, C. H.; Cheng, M. D.; Im, P.; Nawaz, K.; Fricke, B.; Armstrong, A. Characterization of the Indoor Near-Field Aerosol Transmission in a Model Commercial Office Building. *Int. Commun. Heat Mass Transfer* **2021**, 105745. DOI: 10.1016/j.icheatmasstransfer.2021.105745

Dillon, C. F.; Dillon, M. B. Multiscale Airborne Infectious Disease Transmission. *Appl. Environ. Microbiol.* **2021**, 87 (4), e02314-20. DOI: 10.1128/AEM.02314-20

Dillon, M. B.; Dillon, C. F. Regional Relative Risk, a Physics-Based Metric for Characterizing Airborne Infectious Disease Transmission. *Appl. Environ. Microbiol.* **2021**, 87 (21), e01262-21. DOI: 10.1128/AEM.01262-21

Dillon, M. B.; Sextro, R. G.; Delp, W. W. Protecting Building Occupants against the Inhalation of Outdoor-Origin Aerosols. *Atmos. Environ.* **2022**, 268, 118773. DOI: 10.1016/j.atmosenv.2021.118773

Domino, S. P. A Case Study on Pathogen Transport, Deposition, Evaporation and Transmission: Linking High-Fidelity Computational Fluid Dynamics Simulations to Probability of Infection. *International Journal of Computational Fluid Dynamics* **2021**. DOI: 10.1080/10618562.2021.1905801

Fabregat, A.; Gisbert, F.; Vernet, A.; Dutta, S.; Mittal, K.; Pallarès, J. Direct Numerical Simulation of the Turbulent Flow Generated during a Violent Expiratory Event. *Phys. Fluids* **2021**, 33 (3), 035122. DOI: 10.1063/5.0042086

Fabregat, A.; Gisbert, F.; Vernet, A.; Ferré, J. A.; Mittal, K.; Dutta, S.; Pallarès, J. Direct Numerical Simulation of Turbulent Dispersion of Evaporative Aerosol Clouds Produced by an Intense Expiratory Event. *Phys. Fluids* **2021**, 33 (3), 033329. DOI: 10.1063/5.0045416

Fierce, L.; Robey, A. J.; Hamilton, C. Simulating Near-Field Enhancement in Transmission of Airborne Viruses with a Quadrature-Based Model. *Indoor Air* **2021**, 31 (6), 1843–1859. DOI: 10.1111/ina.12900

Ho, C. K.; Binns, R. Modeling and Mitigating Airborne Pathogen Risk Factors in School Buses. *Int. Commun. Heat Mass Transfer* **2021**, 129, 105663. DOI: 10.1016/j.icheatmasstransfer.2021.105663

O'Callahan, B.; Qafoku, O.; Balema, V.; Negrete, O. A.; Passian, A.; Engelhard, M.; Waters, K. M. Atomic Force Microscopy and Infrared Nanospectroscopy of COVID-19 Spike Protein for Quantification of Adhesion to Common Surfaces. *Langmuir* **2021**, 37 (41), 12089–12097. DOI: 10.1021/acs.langmuir.1c01910

Pease, L. F.; Salsbury, T. I.; Anderson, K. K.; Underhill, R. M.; Flaherty, J. E.; Vlachokostas, A.; Burns, C. A.; Wang, N.; Kulkarni, G.; James, D. P. Size Dependent Infectivity of SARS-CoV-2 via Respiratory Droplets Spread through Central Ventilation Systems. *Int. Commun. Heat Mass Transfer* **2021**, 105748. DOI: 10.1016/j.icheatmasstransfer.2021.105748 (Article in special issue “Numerical and Experimental Investigation of Airborne Pathogen Transmission, and Associated Heat and Mass Transfer Processes,” accessed 2021-12-07).

Pease, L. F.; Wang, N.; Salsbury, T. I.; Underhill, R. M.; Flaherty, J. E.; Vlachokostas, A.; Kulkarni, G.; James, D. P. Investigation of Potential Aerosol Transmission and Infectivity of SARS-CoV-2 through Central Ventilation Systems. *Building and Environment* **2021**, 197, 107633. DOI: 10.1016/j.buildenv.2021.107633

Singer, B. C.; Zhao, H.; Preble, C. V.; Delp, W. W.; Pantelic, J.; Sohn, M. D.; Kirchstetter, T. K. Measured Influence of Overhead HVAC on Exposure to Airborne Contaminants from Simulated Speaking in a Meeting and a Classroom. *Indoor Air* **2021**. DOI: 10.1111/ina.12917

Thacher, E.; Carlson, T.; Castellini, J.; Sohn, M. D.; Variano, E.; Mäkiharju, S. A. Droplet and Particle Methods to Investigate Turbulent Particle Laden Jets. *Aerosol Sci. Technol.* **2021**, 55 (12), 1359–1377. DOI: 10.1080/02786826.2021.1959019

# Research Team

## Materials and Manufacturing of Critical Supplies

**Samantha Adikari**

*Los Alamos National Laboratory*

**Daniel Akerib**

*SLAC National Accelerator Laboratory*

**Andrew Ames**

*SLAC National Accelerator Laboratory*

**Marie Arrowsmith**

*Sandia National Laboratories*

**Shaine Athey**

*Lawrence Livermore National Laboratory*

**Celeste Atkins**

*Oak Ridge National Laboratory*

**William Bachman**

*Sandia National Laboratories*

**Teresa Barnes**

*National Renewable Energy Laboratory*

**Abby Barnes**

*Oak Ridge National Laboratory*

**Todd Barrick**

*Sandia National Laboratories*

**Katherine Barrick**

*Sandia National Laboratories*

**Andy Beasley**

*Idaho National Laboratory*

**Clint Bedick**

*National Energy Technology Laboratory*

**Bryan Bellaire**

*Ames Laboratory*

**Donald Benza**

*Savannah River National Laboratory*

**John Bernardin**

*Los Alamos National Laboratory*

**Emma Betters**

*Oak Ridge National Laboratory*

**Randy Bewley**

*Idaho National Laboratory*

**Beth Boardman**

*Los Alamos National Laboratory*

**John Bobbitt**

*Savannah River National Laboratory*

**David Bock**

*Brookhaven National Laboratory*

**Yannick Bomble**

*National Renewable Energy Laboratory*

**Martin Breidenback**

*SLAC National Accelerator Laboratory*

**Michael Bressack**

*SLAC National Accelerator Laboratory*

**Pieter Breur**

*SLAC National Accelerator Laboratory*

**Kevin Byerly**

*National Energy Technology Laboratory*

**Rafael Campos**

*SLAC National Accelerator Laboratory*

**James Carney**

*Sandia National Laboratories*

**Alberta Carpenter**

*National Renewable Energy Laboratory*

**Eric Charles**

*SLAC National Accelerator Laboratory*

**Santanu Chaudhuri**

*Argonne National Laboratory*

**Victor Chavez**  
*Sandia National Laboratories*

**Phillip Chesser**  
*Oak Ridge National Laboratory*

**Wah Chiu**  
*SLAC National Accelerator Laboratory*

**Josef Christ**  
*Pacific Northwest National Laboratory*

**Steven Chu**  
*SLAC National Accelerator Laboratory*

**Peter Ciesielski**  
*National Renewable Energy Laboratory*

**Kyle Cluff**  
*Los Alamos National Laboratory*

**Bruce Cohen**  
*Lawrence Berkeley National Laboratory*

**Adam Cook**  
*Sandia National Laboratories*

**Cody Corbin**  
*Sandia National Laboratories*

**Andres Cortez**  
*Los Alamos National Laboratory*

**Corson Cramer**  
*Oak Ridge National Laboratory*

**Jun Cui**  
*Ames Laboratory*

**Yi Cui**  
*SLAC National Accelerator Laboratory*

**Jeremy Danielson**  
*Los Alamos National Laboratory*

**Nitin Daphalapurkar**  
*Los Alamos National Laboratory*

**Panos Datskos**  
*National Renewable Energy Laboratory*

**Jack Dean**  
*Lawrence Livermore National Laboratory*

**Vincent DeAndrade**  
*Argonne National Laboratory*

**Haedi Deangelis**  
*Sandia National Laboratories*

**Ryan Dehoff**  
*Oak Ridge National Laboratory*

**Patrick Dempsey**  
*Lawrence Livermore National Laboratory*

**Alexander Dudchenko**  
*SLAC National Accelerator Laboratory*

**Eric Duoss**  
*Lawrence Livermore National Laboratory*

**Steve Eglash**  
*SLAC National Accelerator Laboratory*

**Jeffrey Elam**  
*Argonne National Laboratory*

**Amy Elliott**  
*Oak Ridge National Laboratory*

**Ken Enstrom**  
*Lawrence Livermore National Laboratory*

**Rebecca Erikson**  
*Pacific Northwest National Laboratory*

**Tom Feldhausen**  
*Oak Ridge National Laboratory*

**Michelle Fenn**  
*Pacific Northwest National Laboratory*

**Don Ferguson**  
*National Energy Technology Laboratory*

**Patrick Finnegan**  
*Sandia National Laboratories*

**Matthew Folsom**  
*Savannah River National Laboratory*

**Dennis Freeman**  
*Lawrence Livermore National Laboratory*

**William Fuger**  
*Idaho National Laboratory*

**Nathan Fuller**  
*Sandia National Laboratories*

**Jon Fulton**  
*National Energy Technology Laboratory*

**David Gaga**  
*SLAC National Accelerator Laboratory*

**Kumkum Ganguly**  
*Los Alamos National Laboratory*

**Randall Gentry**  
*National Energy Technology Laboratory*

**Kevin Gervais**  
*Pacific Northwest National Laboratory*

**Jeremy Gleick**  
*Lawrence Livermore National Laboratory*

**Andrew Glen**  
*Sandia National Laboratories*



**John Greenhall**  
*Los Alamos National Laboratory*

**Lisa Gribble**  
*Sandia National Laboratories*

**Anne Grillet**  
*Sandia National Laboratories*

**Lorenzo Gutierrez**  
*Sandia National Laboratories*

**Steven Guzorek**  
*Lawrence Livermore National Laboratory*

**Ryan Haggerty**  
*Sandia National Laboratories*

**Michael Ham**  
*Los Alamos National Laboratory*

**Razi Haque**  
*Lawrence Livermore National Laboratory*

**Jennifer Harris**  
*Los Alamos National Laboratory*

**Marcus Hays**  
*Argonne National Laboratory*

**Ryan Herbst**  
*SLAC National Accelerator Laboratory*

**Chris Hershey**  
*Oak Ridge National Laboratory*

**Michael Himmel**  
*National Renewable Energy Laboratory*

**Andrew Honeycutt**  
*Oak Ridge National Laboratory*

**Nick Horvath**  
*Oak Ridge National Laboratory*

**Peter Hosemann**  
*Lawrence Berkeley National Laboratory*

**Peter Hsieh**  
*National Energy Technology Laboratory*

**Christina Ignarra**  
*SLAC National Accelerator Laboratory*

**Ralph James**  
*Savannah River National Laboratory*

**Todd Jankowski**  
*Los Alamos National Laboratory*

**Dale Jenne**  
*National Renewable Energy Laboratory*

**Jing Jin**  
*SLAC National Accelerator Laboratory*

**Joel Johnson**  
*Idaho National Laboratory*

**Robert Johnston**  
*Sandia National Laboratories*

**Mike Kirka**  
*Oak Ridge National Laboratory*

**Matthew Koetting**  
*Kansas City National Security Campus*

**Jeffrey Koplrow**  
*Sandia National Laboratories*

**Jack Kotovsky**  
*Lawrence Livermore National Laboratory*

**Gary Krugger**  
*Los Alamos National Laboratory*

**Gregory Krumdick**  
*Argonne National Laboratory*

**Wendy Kuhne**  
*Savannah River National Laboratory*

**Ian Ladner**  
*Lawrence Livermore National Laboratory*

**Justin Lajoie**  
*Ames Laboratory*

**Candace Langan**  
*Savannah River National Laboratory*

**Greg Larsen**  
*Oak Ridge National Laboratory*

**Matthew Lee**  
*Los Alamos National Laboratory*

**Thomas Lewis**  
*Idaho National Laboratory*

**John Lindahl**  
*Oak Ridge National Laboratory*

**Peter Lloyd**  
*Oak Ridge National Laboratory*

**Thomas Lograsso**  
*Ames Laboratory*

**Lonnie Love**  
*Oak Ridge National Laboratory*

**Steffen Luitz**  
*SLAC National Accelerator Laboratory*

**Leah Lujan**  
*Los Alamos National Laboratory*

**Therese Lujan**  
*Los Alamos National Laboratory*

**Monear Makvandi**  
Sandia National Laboratories

**Dan Manha**  
Lawrence Livermore National Laboratory

**Ruben Manzanares**  
Los Alamos National Laboratory

**Alex Marchi**  
Los Alamos National Laboratory

**Amy Marschilok**  
Brookhaven National Laboratory

**Adam Martinez**  
Los Alamos National Laboratory

**Mathew Mate**  
SLAC National Accelerator Laboratory

**Chris Matranga**  
National Energy Technology Laboratory

**Michael Maxwell**  
Savannah River National Laboratory

**Sean McGaughey**  
Pacific Northwest National Laboratory

**Eric Miller**  
SLAC National Accelerator Laboratory

**Doug Modlin**  
Lawrence Livermore National Laboratory

**Marwan Mohamed**  
Los Alamos National Laboratory

**Arvind Mohan**  
Los Alamos National Laboratory

**Brian Mong**  
SLAC National Accelerator Laboratory

**Patrick Moo**  
Idaho National Laboratory

**Murray Moore**  
Los Alamos National Laboratory

**Robert Morgan**  
Los Alamos National Laboratory

**Monica Moya**  
Lawrence Livermore National Laboratory

**Elvin Munoz**  
Pacific Northwest National Laboratory

**Du Nguyen**  
Lawrence Livermore National Laboratory

**Greg Norton**  
Lawrence Livermore National Laboratory

**David Nuttall**  
Oak Ridge National Laboratory

**Andrzej Nycz**  
Oak Ridge National Laboratory

**Austin Nye**  
Lawrence Livermore National Laboratory

**Robert O'Brien**  
Idaho National Laboratory

**Michael Omana**  
Sandia National Laboratories

**Scott Paap**  
Sandia National Laboratories

**Cristian Pantea**  
Los Alamos National Laboratory

**Parans Paranthaman**  
Oak Ridge National Laboratory

**Phil Paul**  
Lawrence Livermore National Laboratory

**Jeremy Payton**  
Los Alamos National Laboratory

**Martin Perraglio**  
Los Alamos National Laboratory

**Matt Pharr**  
Lawrence Livermore National Laboratory

**Brian Post**  
Oak Ridge National Laboratory

**Krzysztof Pupek**  
Argonne National Laboratory

**Samantha Reese**  
National Renewable Energy Laboratory

**Steve Richardson**  
National Energy Technology Laboratory

**Bryce Ricken**  
Sandia National Laboratories

**Jacob Riglin**  
Los Alamos National Laboratory

**Jason Roadman**  
National Renewable Energy Laboratory

**Larry Rodriguez**  
Los Alamos National Laboratory

**Mohammad Roni**  
Idaho National Laboratory

**Alex Roschli**  
Oak Ridge National Laboratory

**Alexander Rose**  
*Los Alamos National Laboratory*

**Michael Sabo**  
*Sandia National Laboratories*

**Bradley Salzbrenner**  
*Sandia National Laboratories*

**Andres Sanchez**  
*Sandia National Laboratories*

**Daniel Schabacker**  
*Argonne National Laboratory*

**Andrew Schmalzer**  
*Los Alamos National Laboratory*

**Patrick Scholl**  
*Lawrence Livermore National Laboratory*

**Eric Shaner**  
*Sandia National Laboratories*

**Maxim Shusteff**  
*Lawrence Livermore National Laboratory*

**Randall Schunk**  
*Sandia National Laboratories*

**Tom Shutt**  
*SLAC National Accelerator Laboratory*

**Graham Simmons**  
*SLAC National Accelerator Laboratory*

**Michael Sinclair**  
*Sandia National Laboratories*

**Julie Slaughter**  
*Ames Laboratory*

**Denver Smith**  
*Los Alamos National Laboratory*

**Scott Smith**  
*Oak Ridge National Laboratory*

**Brittnee Smith**  
*Pacific Northwest National Laboratory*

**David Soscia**  
*Lawrence Livermore National Laboratory*

**Christopher Spadaccini**  
*Lawrence Livermore National Laboratory*

**Dusan Spornjak**  
*Los Alamos National Laboratory*

**Aaron Sperry**  
*Lawrence Livermore National Laboratory*

**Mike Steinzig**  
*Los Alamos National Laboratory*

**Christopher Takacs**  
*SLAC National Accelerator Laboratory*

**Deepti Tanjore**  
*Lawrence Berkeley National Laboratory*

**Bryce Tappan**  
*Los Alamos National Laboratory*

**Antionette Taylor**  
*Los Alamos National Laboratory*

**Paul Thelen**  
*Sandia National Laboratories*

**Merlin Theodore**  
*Oak Ridge National Laboratory*

**Angela Tooker**  
*Lawrence Livermore National Laboratory*

**Katherine Tremba**  
*Sandia National Laboratories*

**Michael Triplett**  
*Lawrence Livermore National Laboratory*

**Jacob Trueblood**  
*Lawrence Livermore National Laboratory*

**Charles Turick**  
*Savannah River National Laboratory*

**Jeffrey Urban**  
*Lawrence Berkeley National Laboratory*

**Victor Vargas**  
*Lawrence Livermore National Laboratory*

**Vanessa Vargas**  
*Sandia National Laboratories*

**Joshua Vaughan**  
*Oak Ridge National Laboratory*

**Eliel Villa-Aleman**  
*Savannah River National Laboratory*

**Lei Wang**  
*Brookhaven National Laboratory*

**Peter Wang**  
*Oak Ridge National Laboratory*

**Scott Weaver**  
*SLAC National Accelerator Laboratory*

**Nina Weisse-Bernstein**  
*Los Alamos National Laboratory*

**Dora Wiemann**  
*Sandia National Laboratories*

**Brian Wihl**  
*Lawrence Livermore National Laboratory*



**Zachary Wilson**  
Sandia National Laboratories

**Edward Winrow**  
Sandia National Laboratories

**Matthias Wittgen**  
SLAC National Accelerator Laboratory

**Shan Yan**  
Brookhaven National Laboratory

**Allison Yorita**  
Lawrence Livermore National Laboratory

**Qinghui Yuan**  
Argonne National Laboratory

**Yuepeng Zhang**  
Argonne National Laboratory

## Molecular Design for COVID-19 Therapeutics

**Paul Adams**  
Lawrence Berkeley National Laboratory

**Nanda Aduri**  
SLAC National Accelerator Laboratory

**Chase Akins**  
Argonne National Laboratory

**Jonathan Allen**  
Lawrence Livermore National Laboratory

**Marc Alvarez**  
Los Alamos National Laboratory

**Lindsey Anderson**  
Pacific Northwest National Laboratory

**Babak Andi**  
Brookhaven National Laboratory

**Gyorgy Babnigg**  
Argonne National Laboratory

**Yadu Babuji**  
Argonne National Laboratory

**Alexander Batyuk**  
SLAC National Accelerator Laboratory

**Kellon Belfon**  
Stony Brook University

**Debsindhu Bhowmik**  
Oak Ridge National Laboratory

**Benjamin Blaiszik**  
Argonne National Laboratory

**Swen Boehm**  
Oak Ridge National Laboratory

**Peter Bonnesen**  
Oak Ridge National Laboratory

**Jim Brase**  
Lawrence Livermore National Laboratory

**Tom Brettin**  
Argonne National Laboratory

**James Brown**  
Lawrence Berkeley National Laboratory

**Garry Buchko**  
Pacific Northwest National Laboratory

**Seth Carbon**  
Lawrence Berkeley National Laboratory

**Kyle Chard**  
University of Chicago

**Ryan Chard**  
Argonne National Laboratory

**Andrew Chen**  
Lawrence Berkeley National Laboratory

**Julian Chen**  
Los Alamos National Laboratory

**Samuel Chen**  
Brookhaven National Laboratory

**Wah Chiu**  
SLAC National Accelerator Laboratory

**Nicholas Choma**  
Lawrence Berkeley National Laboratory

**Austin Clyde**  
Argonne National Laboratory

**Leighton Coates**  
Oak Ridge National Laboratory

**Matthew (Matt) Coleman**  
Lawrence Livermore National Laboratory

**Connor Cooper**  
Oak Ridge National Laboratory

**Abbigayle (Abby) Cuomo**  
Stony Brook University

**Andy DeGiovanni**  
Lawrence Berkeley National Laboratory

**Thomas Desautels**  
Lawrence Livermore National Laboratory

**Emily Dietrich**  
Argonne National Laboratory

**Peng Ding**  
Argonne National Laboratory

**Mitchel Doktycz**

*Oak Ridge National Laboratory*

**Xiaotian Duan**

*University of Chicago*

**Chris Ellis**

*Oak Ridge National Laboratory*

**Aidan Epstein**

*Lawrence Livermore National Laboratory*

**Daniel Faissol**

*Lawrence Livermore National Laboratory*

**Lucy Fallon**

*Stony Brook University*

**Yichong Fan**

*Oak Ridge National Laboratory*

**Song Feng**

*Pacific Northwest National Laboratory*

**William Fischer**

*Los Alamos National Laboratory*

**Nicholas (Nick) Fischer**

*Lawrence Livermore National Laboratory*

**Ian Foster**

*Argonne National Laboratory*

**Magdalena (Magda) Franco**

*Lawrence Livermore National Laboratory*

**Stephanie Galanie**

*Oak Ridge National Laboratory*

**Carlos Gamboa**

*Brookhaven National Laboratory*

**Umamaheswari Ganapathy**

*Brookhaven National Laboratory*

**Cornelius Gati**

*SLAC National Accelerator Laboratory*

**Sandrasegaram Gnanakaran**

*Los Alamos National Laboratory*

**Jose Guerra**

*Stony Brook University*

**Mikhail Hameedi**

*SLAC National Accelerator Laboratory*

**Brooke Harmon**

*Sandia National Laboratories*

**Nomi Harris**

*Lawrence Berkeley National Laboratory*

**Darin Hauner**

*Pacific Northwest National Laboratory*

**Stewart He**

*Lawrence Livermore National Laboratory*

**Martha (Marti) Head**

*Oak Ridge National Laboratory*

**Dean Hidas**

*Brookhaven National Laboratory*

**Elijah Hoffman**

*Lawrence Berkeley National Laboratory*

**Kunlun Hong**

*Oak Ridge National Laboratory*

**Zhi Hong**

*University of Chicago*

**Naoki Horikoshi**

*SLAC National Accelerator Laboratory*

**Kim Hoshin**

*Pacific Northwest National Laboratory*

**Mark Hunter**

*SLAC National Accelerator Laboratory*

**Stephan Irle**

*Oak Ridge National Laboratory*

**Srinivas Iyer**

*Los Alamos National Laboratory*

**Daniel Jacobson**

*Oak Ridge National Laboratory*

**Rhema James**

*Pacific Northwest National Laboratory*

**Songhao Jiang**

*Argonne National Laboratory*

**Marcin Joachimiak**

*Lawrence Berkeley National Laboratory*

**Jessica Johnson**

*Argonne National Laboratory*

**Rajendra Joshi**

*Pacific Northwest National Laboratory*

**Ai Kagawa**

*Brookhaven National Laboratory*

**Richard Keith**

*Lawrence Berkeley National Laboratory*

**Michael Kent**

*Sandia National Laboratories*

**Vilmos Kertesz**

*Oak Ridge National Laboratory*

**Kerstin Kleese van Dam**

*Brookhaven National Laboratory*

**Daniel Kneller**  
Oak Ridge National Laboratory

**Bette Korber**  
Los Alamos National Laboratory

**Andrii Kovalevskyi**  
Oak Ridge National Laboratory

**Kristen (Kris) Kulp**  
Lawrence Livermore National Laboratory

**Neeraj Kumar**  
Pacific Northwest National Laboratory

**Audrey Labbé**  
Oak Ridge National Laboratory

**Joshua Ladau**  
Lawrence Berkeley National Laboratory

**Edmond Lau**  
Lawrence Livermore National Laboratory

**Joseph Laureanti**  
Pacific Northwest National Laboratory

**Wellington Leite**  
Oak Ridge National Laboratory

**Zhouzhao Li**  
University of Chicago

**Felice Lightstone**  
Lawrence Livermore National Laboratory

**Xuefeng Liu**  
Argonne National Laboratory

**Heng Ma**  
Argonne National Laboratory

**Carla Mann**  
Argonne National Laboratory

**Irimpan Mathews**  
SLAC National Accelerator Laboratory

**Stefan Maxwell**  
Sandia National Laboratories

**Sean McCorkle**  
Brookhaven National Laboratory

**Jason McDermott**  
Pacific Northwest National Laboratory

**Kevin McLoughlin**  
Lawrence Livermore National Laboratory

**Sean McSweeney**  
Brookhaven National Laboratory

**Ryszard Michalczyk**  
Los Alamos National Laboratory

**Chris Mungall**  
Lawrence Berkeley National Laboratory

**Daniel Murphy-Olson**  
Argonne National Laboratory

**Oscar Negrete**  
Sandia National Laboratories

**Peter Nugent**  
Lawrence Berkeley National Laboratory

**Carlos Olivares-Reboredo**  
University of Chicago

**Hugh O'Neill**  
Oak Ridge National Laboratory

**Swati Pant**  
Oak Ridge National Laboratory

**Jerry Parks**  
Oak Ridge National Laboratory

**Alexander Partin**  
Argonne National Laboratory

**Jose Pereira**  
Lawrence Berkeley National Laboratory

**Gwendalyn Phillips**  
Oak Ridge National Laboratory

**Sai Venkatesh Pingali**  
Oak Ridge National Laboratory

**Martin Purschke**  
Brookhaven National Laboratory

**Emily Purvine**  
Pacific Northwest National Laboratory

**Shuo Qian**  
Oak Ridge National Laboratory

**Xiaohui Qu**  
Brookhaven National Laboratory

**Lauren Raguette**  
Stony Brook University

**Maksim Rakitin**  
Brookhaven National Laboratory

**Arvind Ramanathan**  
Argonne National Laboratory

**Simone Raugei**  
Pacific Northwest National Laboratory

**Justin Reese**  
Lawrence Berkeley National Laboratory

**Yihui Ren**  
Brookhaven National Laboratory



**Andria Rodrigues**  
*Lawrence Berkeley National Laboratory*

**Nickolaus Saint**  
*Argonne National Laboratory*

**Kenneth Sale**  
*Sandia National Laboratories*

**Brian Sanders**  
*Oak Ridge National Laboratory*

**Anthony Savushkin**  
*Argonne National Laboratory*

**Jurgen Schmidt**  
*Los Alamos National Laboratory*

**Joe Schoeniger**  
*Sandia National Laboratories*

**Ashka Sha**  
*University of Chicago*

**Carlos Simmerling**  
*Stony Brook University*

**Suhas Somnath**  
*Oak Ridge National Laboratory*

**Chris Stanley**  
*Oak Ridge National Laboratory*

**Darya (Dasha) Stepanenko**  
*Stony Brook University*

**Rick Stevens**  
*Argonne National Laboratory*

**Jacob Sumner**  
*Oak Ridge National Laboratory*

**Li Tan**  
*Brookhaven National Laboratory*

**Oleg Tchoubar**  
*Brookhaven National Laboratory*

**Marisa Torres**  
*Lawrence Livermore National Laboratory*

**Anda Trifan**  
*Argonne National Laboratory*

**Deepak Unni**  
*Lawrence Berkeley National Laboratory*

**Hubertus van Dam**  
*Brookhaven National Laboratory*

**Van Vuong**  
*Oak Ridge National Laboratory*

**Rick Wagner**  
*University of California San Diego*

**Soichi Wakatsuki**  
*SLAC National Accelerator Laboratory*

**Yuzhang Wang**  
*Stony Brook University*

**Logan Ward**  
*Argonne National Laboratory*

**Katrina Waters**  
*Pacific Northwest National Laboratory*

**Amber Webb**  
*Oak Ridge National Laboratory*

**Bobbie-Jo Webb-Robertson**  
*Pacific Northwest National Laboratory*

**Kevin Weiss**  
*Oak Ridge National Laboratory*

**Kelly Williams**  
*Sandia National Laboratories*

**Sergio Wong**  
*Lawrence Livermore National Laboratory*

**Yulun Wu**  
*Lawrence Berkeley National Laboratory*

**Yue Yang**  
*Lawrence Livermore National Laboratory*

**Hyunseung Yoo**  
*Argonne National Laboratory*

**Qiu Zhang**  
*Oak Ridge National Laboratory*

**Mowei Zhou**  
*Pacific Northwest National Laboratory*

**Fangqiang Zhu**  
*Lawrence Livermore National Laboratory*

**Ying Zhu**  
*Pacific Northwest National Laboratory*

## COVID-19 Testing

**Rebecca Abergel**  
*Lawrence Berkeley National Laboratory*

**Paul Adams**  
*Lawrence Berkeley National Laboratory*

**Dion Antonopoulos**  
*Argonne National Laboratory*

**Gyorgy Babnigg**  
*Argonne National Laboratory*

**Scott Baker**  
*Pacific Northwest National Laboratory*

**Daniel Bedinger***Carterra***Monica Borucki***Lawrence Livermore National Laboratory***Steven B. Bradfute***University of New Mexico***Thomas Bunt***Lawrence Livermore National Laboratory***Chris Daum***Lawrence Livermore National Laboratory***Patrick Fitch***Los Alamos National Laboratory***Vince Gerbasi***Pacific Northwest National Laboratory***Paul Gilna***Oak Ridge National Laboratory***David Graham***Oak Ridge National Laboratory***Michael Guarnieri***National Renewable Energy Laboratory***Sally Hall***Lawrence Livermore National Laboratory***Nathan Hillson***Lawrence Berkeley National Laboratory***Elizabeth Hong-Geller***Los Alamos National Laboratory***Greg Hura***Lawrence Berkeley National Laboratory***Crystal Jaing***Lawrence Livermore National Laboratory***Ramesh Jha***Los Alamos National Laboratory***Andrzej Joachimiak***Argonne National Laboratory***Bishoy Kamel***Lawrence Berkeley National Laboratory***Jeff Kimbrel***Lawrence Livermore National Laboratory***Antonietta M. Lillo***Los Alamos National Laboratory***Betty Mangadu***Sandia National Laboratories***Robert Meagher***Sandia National Laboratories***Joseph Moon***Lawrence Livermore National Laboratory***Nigel Mouncey***Lawrence Berkeley National Laboratory/DOE Joint Genome Institute***Michael Morrison***Lawrence Livermore National Laboratory***Nisha Mulakken***Lawrence Livermore National Laboratory***Hau Nguyen***Los Alamos National Laboratory***Marit Nilsen-Hamilton***Ames Laboratory***Kristin Omberg***Pacific Northwest National Laboratory***Hugh O'Neal***Oak Ridge National Laboratory***Jerry Parks***Oak Ridge National Laboratory***Lili Pasa-Tolic***Pacific Northwest National Laboratory***Christa Pennacchio***Lawrence Berkeley National Laboratory***Dave Rakestraw***Lawrence Livermore National Laboratory***Scott Retterer***Oak Ridge National Laboratory***Marc Salit***SLAC National Accelerator Laboratory***Blake Simmons***Lawrence Berkeley National Laboratory***Anup Singh***Sandia National Laboratories, now Lawrence Livermore National Laboratory***Jess Sustarich***Sandia National Laboratories***James Thissen***Lawrence Livermore National Laboratory***Nileena Velappan***Los Alamos National Laboratory***Geoff Waldo***Los Alamos National Laboratory***Kelly Williams***Sandia National Laboratories*

**Jesse Wilson**  
*Pacific Northwest National Laboratory*

**Chunyan Ye**  
*University of New Mexico*

**Malin Young**  
*Pacific Northwest National Laboratory*

**Yuko Yoshinaga**  
*Lawrence Berkeley National Laboratory*

**Mowei Zhou**  
*Pacific Northwest National Laboratory*

## **Epidemiological Modeling**

**Erin Acquesta**  
*Sandia National Laboratories*

**James Ahrens**  
*Los Alamos National Laboratory*

**Joshua Auld**  
*Argonne National Laboratory*

**Paula Austin**  
*Sandia National Laboratories*

**Ryan Aydelott**  
*Argonne National Laboratory*

**Andrew Bartlow**  
*Los Alamos National Laboratory*

**Joshua Bergerson**  
*Argonne National Laboratory*

**Anne Berres**  
*Oak Ridge National Laboratory*

**Walter Beyeler**  
*Sandia National Laboratories*

**Budhendra Bhaduri**  
*Oak Ridge National Laboratory*

**Alec Biehl**  
*Oak Ridge National Laboratory*

**Patrick Blonigan**  
*Sandia National Laboratories*

**Brennan Borlaug**  
*National Renewable Energy Laboratory*

**Christa Brelsford**  
*Oak Ridge National Laboratory*

**Benjamin Brodsky**  
*Sandia National Laboratories*

**Lauren Castro**  
*Los Alamos National Laboratory*

**Youngsoo Chang**  
*Argonne National Laboratory*

**Supriya Chinthavali**  
*Oak Ridge National Laboratory*

**Blair Christian**  
*Oak Ridge National Laboratory*

**Timothy Cleland**  
*Los Alamos National Laboratory*

**Nicholson Collier**  
*Argonne National Laboratory*

**Scott Collis**  
*Sandia National Laboratories*

**Jessica Conrad**  
*Los Alamos National Laboratory*

**Elton Cranfill**  
*Oak Ridge National Laboratory*

**Leticia Cuellar-Hengartner**  
*Los Alamos National Laboratory*

**Chad Davis**  
*Sandia National Laboratories*

**Lori Dauelsberg**  
*Los Alamos National Laboratory*

**Rich Davies**  
*Oak Ridge National Laboratory*

**Haedi DeAngelis**  
*Sandia National Laboratories*

**Sean DeRosa**  
*Sandia National Laboratories*

**Sara Del Valle**  
*Los Alamos National Laboratory*

**Bradley Dickerson**  
*Sandia National Laboratories*

**Andrew Duvall**  
*National Renewable Energy Laboratory*

**Samantha Erwin**  
*Oak Ridge National Laboratory*

**Mary Ewers**  
*Los Alamos National Laboratory*

**Jeanne Fair**  
*Los Alamos National Laboratory*

**Geoffrey Fairchild**  
*Los Alamos National Laboratory*

**John Farrell**  
*National Renewable Energy Laboratory*



**Kyle Feffer**  
*Argonne National Laboratory*

**Paul Fenimore**  
*Los Alamos National Laboratory*

**Melissa Finley**  
*Sandia National Laboratories*

**Patrick Finley**  
*Sandia National Laboratories*

**Joseph Fish**  
*National Renewable Energy Laboratory*

**Michael Ford**  
*Sandia National Laboratories*

**Christopher Frazier**  
*Sandia National Laboratories*

**Venu Garikapati**  
*National Renewable Energy Laboratory*

**Jared Gearhart**  
*Sandia National Laboratories*

**Timothy German**  
*Los Alamos National Laboratory*

**Dax Gerts**  
*Los Alamos National Laboratory*

**Phwey “Danny” Gil**  
*Argonne National Laboratory*

**Morgan Gorris**  
*Los Alamos National Laboratory*

**Josh Grant**  
*Oak Ridge National Laboratory*

**Ann Hammer**  
*Sandia National Laboratories*

**Desmond Harmon**  
*Sandia National Laboratories*

**Nicolas Hengartner**  
*Los Alamos National Laboratory*

**Michael Hilliard**  
*Oak Ridge National Laboratory*

**William Hlavacek**  
*Los Alamos National Laboratory*

**Rossitza Homan**  
*Sandia National Laboratories*

**John Hummel**  
*Argonne National Laboratory*

**Aundre Huynh**  
*Sandia National Laboratories*

**Ho-Ling Hwang**  
*Oak Ridge National Laboratory*

**Brian Ingram**  
*Argonne National Laboratory*

**Dean Jones**  
*Sandia National Laboratories*

**Jessica Jones**  
*Sandia National Laboratories*

**Kyungsoo Jeong**  
*National Renewable Energy Laboratory*

**Chaitanya Kaligotla**  
*Argonne National Laboratory*

**Jason Kaufman**  
*Oak Ridge National Laboratory*

**Thomas Kirchstetter**  
*Lawrence Berkeley National Laboratory*

**Katherine Klise**  
*Sandia National Laboratories*

**Daniel Krofcheck**  
*Sandia National Laboratories*

**Haitam Laarabi**  
*Lawrence Berkeley National Laboratory*

**Diane Lauderdale**  
*Argonne National Laboratory*

**Rene Leclaire**  
*Los Alamos National Laboratory*

**David LePoire**  
*Argonne National Laboratory*

**Drew Levin**  
*Sandia National Laboratories*

**Lawrence Paul Lewis**  
*Argonne National Laboratory*

**Yen Ting Lin**  
*Los Alamos National Laboratory*

**Charles Macal**  
*Argonne National Laboratory*

**Margaret MacDonell**  
*Sandia National Laboratories*

**Monear Makvandi**  
*Sandia National Laboratories*

**Carrie Manore**  
*Los Alamos National Laboratory*

**Carianne Martinez**  
*Sandia National Laboratories*

**Ignacio Martinez-Moyano**

*Argonne National Laboratory*

**Taylor McKenzie**

*Sandia National Laboratories*

**Benjamin McMahon**

*Los Alamos National Laboratory*

**Isaac Michaud**

*Los Alamos National Laboratory*

**Mike Mills**

*Lawrence Berkeley National Laboratory*

**Jacob Miner**

*Los Alamos National Laboratory*

**Jessica Moehl**

*Oak Ridge National Laboratory*

**Matthew Moniot**

*National Renewable Energy Laboratory*

**Judith Mourant**

*Los Alamos National Laboratory*

**Aaron Myers**

*Oak Ridge National Laboratory*

**Zach Needell**

*Lawrence Berkeley National Laboratory*

**David Osthus**

*Los Alamos National Laboratory*

**Jonathan Ozik**

*Argonne National Laboratory*

**Byung Park**

*Oak Ridge National Laboratory*

**Nidhi Parkh**

*Los Alamos National Laboratory*

**Alina Peluso**

*Oak Ridge National Laboratory*

**Jordan Perr-Sauer**

*National Renewable Energy Laboratory*

**Sinem Perk**

*Argonne National Laboratory*

**Frederic Petit**

*Argonne National Laboratory*

**Jesse Piburn**

*Oak Ridge National Laboratory*

**Teresa Portone**

*Sandia National Laboratories*

**Julia Potter**

*Sandia National Laboratories*

**Rosalyn Rael**

*Los Alamos National Laboratory*

**Phillip Rauscher**

*Argonne National Laboratory*

**Srinath Ravulaparthi**

*Lawrence Berkeley National Laboratory*

**Jaideep Ray**

*Sandia National Laboratories*

**Nicholas Reinicke**

*National Renewable Energy Laboratory*

**Sara Rimer**

*Argonne National Laboratory*

**Mark “Danny” Rintoul**

*Sandia National Laboratories*

**Amy Rose**

*Oak Ridge National Laboratory*

**William Rosenberger**

*Los Alamos National Laboratory*

**Aymeric Rousseau**

*Argonne National Laboratory*

**Angelika Saeger**

*Los Alamos National Laboratory*

**Cosmin Safta**

*Sandia National Laboratories*

**Erik Schmidt**

*Oak Ridge National Laboratory*

**Scott Schlueter**

*Argonne National Laboratory*

**Courtney Shelley**

*Los Alamos National Laboratory*

**Anup Singh**

*Sandia National Laboratories*

**Nagendra Singh**

*Oak Ridge National Laboratory*

**Braeton Smith**

*Argonne National Laboratory*

**Asael Sorensen**

*Sandia National Laboratories*

**Alex Sorokine**

*Oak Ridge National Laboratory*

**Tina Sowers**

*Oak Ridge National Laboratory*

**Kevin Sparks**

*Oak Ridge National Laboratory*

**Pamela Spetz***Argonne National Laboratory***Anna Spurlock***Lawrence Berkeley National Laboratory***Abby Stevens***Argonne National Laboratory***Robert Stewart***Oak Ridge National Laboratory***Bingrong Sun***National Renewable Energy Laboratory***Laura Swiler***Sandia National Laboratories***Varisara Tansakul***Oak Ridge National Laboratory***Robert Taylor***Sandia National Laboratories***Kirsten Taylor-McCabe***Los Alamos National Laboratory***Gautam Thakur***Oak Ridge National Laboratory***Katherine Tremba***Sandia National Laboratories***Lawrence Trost***Sandia National Laboratories***Majbah Uddin***Oak Ridge National Laboratory***Vanessa Vargas***Sandia National Laboratories***Omer Verbas***Argonne National Laboratory***Sarah Voter***Los Alamos National Laboratory***Amanda Wagner***Argonne National Laboratory***Laurie Wallis***Sandia National Laboratories***Cheng Wang***Argonne National Laboratory***Ross Wang***Oak Ridge National Laboratory***Rashid Waraich***Lawrence Berkeley National Laboratory***Chrysm Watson***Los Alamos National Laboratory***Eric Webber***Oak Ridge National Laboratory***Tom Wenzel***Lawrence Berkeley National Laboratory***Celine West***Sandia National Laboratories***Matthew Whitehead***Oak Ridge National Laboratory***Kristen Wilding***Los Alamos National Laboratory***Alana Wilson***National Renewable Energy Laboratory***Murray Wolinsky***Los Alamos National Laboratory***Justin Wozniak***Argonne National Laboratory***Fei Xie***Oak Ridge National Laboratory***Haowen Xu***Oak Ridge National Laboratory***Stanley Young***National Renewable Energy Laboratory***Zijia Zhong***National Renewable Energy Laboratory***Viral Fate and Transport****Jesse Ahlquist***Lawrence Livermore National Laboratory***Allison Aiken***Los Alamos National Laboratory***Kevin Anderson***Pacific Northwest National Laboratory***Ramesh Balakrishnan***Argonne National Laboratory***Viktor Balema***Ames Laboratory***Bryan Bellaire***Iowa State University***Robin Brigmon***Savannah River National Laboratory***Michael J. Brown***Los Alamos National Laboratory***Carolyn Burns***Pacific Northwest National Laboratory*



**Jules Cacho**

*Argonne National Laboratory*

**Jack Cahill**

*Oak Ridge National Laboratory*

**Andrew Costinett**

*Pacific Northwest National Laboratory*

**Richard Daniel**

*Pacific Northwest National Laboratory*

**William Delp**

*Lawrence Berkeley National Laboratory*

**Armand Dichosa**

*Los Alamos National Laboratory*

**Michael Dillon**

*Lawrence Livermore National Laboratory*

**Liz Dobitz**

*SLAC National Accelerator Laboratory*

**Stefan Paul Domino**

*Sandia National Laboratories*

**Mavendra Dubey**

*Los Alamos National Laboratory*

**Som Dutta**

*Utah State University*

**Anne Marie Erler**

*Lawrence Livermore National Laboratory*

**Yan Feng**

*Argonne National Laboratory*

**Laura Fierce**

*Brookhaven National Laboratory, now Pacific Northwest National Laboratory*

**Paul Fischer**

*University of Illinois at Urbana-Champaign*

**Julia Flaherty**

*Pacific Northwest National Laboratory*

**Erika Fong**

*Lawrence Livermore National Laboratory*

**Laura Forde**

*Lawrence Livermore National Laboratory*

**Matthias Frank**

*Lawrence Livermore National Laboratory*

**Brian Fricke**

*Oak Ridge National Laboratory*

**Brad Fritz**

*Pacific Northwest National Laboratory*

**Jamie George**

*Pacific Northwest National Laboratory*

**Andrew Glen**

*Sandia National Laboratories*

**Kyle Gorkowski**

*Los Alamos National Laboratory*

**Larry Hamm**

*Savannah River National Laboratory*

**Ihor Hlova**

*Ames Laboratory*

**Clifford Ho**

*Sandia National Laboratories*

**Dan James**

*Pacific Northwest National Laboratory*

**Staci Kane**

*Lawrence Livermore National Laboratory*

**Thomas Kirchstetter**

*Lawrence Berkeley National Laboratory*

**Rao Kotamarthi**

*Argonne National Laboratory*

**Gourihar Kulkarni**

*Pacific Northwest National Laboratory*

**Brady Lee**

*Savannah River National Laboratory*

**Patricia Lee**

*Savannah River National Laboratory*

**Robert Lutes**

*Pacific Northwest National Laboratory*

**Naila Mahdi**

*Argonne National Laboratory*

**Simo Makiharju**

*University of California, Berkeley*

**Bob McGraw**

*Brookhaven National Laboratory*

**Richard Mills**

*Argonne National Laboratory*

**Kashif Nawaz**

*Oak Ridge National Laboratory*

**Oscar Negrete**

*Sandia National Laboratories*

**Cristina Negri**

*Argonne National Laboratory*

**Ralph Nichols**

*Savannah River National Laboratory*

**Aleks Obabko**

*Argonne National Laboratory*

**Brian O’Callahan**  
*Pacific Northwest National Laboratory*

**Ronald Ott**  
*Oak Ridge National Laboratory*

**Aaron Packman**  
*Northwestern University*

**Jovan Pantelic**  
*University of California, Berkeley*

**Ali Passian**  
*Oak Ridge National Laboratory*

**Leonard Pease**  
*Pacific Northwest National Laboratory*

**Kruttika-Suhas Phadke**  
*Iowa State University*

**Chelsea Preble**  
*University of California, Berkeley*

**Tanya Prozorov**  
*Ames Laboratory*

**Odeta Qafoku**  
*Pacific Northwest National Laboratory*

**John Quinn**  
*Argonne National Laboratory*

**Edwin Saavedra**  
*Northwestern University*

**Anne Sakdinawat**  
*SLAC National Accelerator Laboratory*

**Timothy Salsbury**  
*Pacific Northwest National Laboratory*

**Andres Lorenzo Sanchez**  
*Sandia National Laboratories*

**Callen Schwefler**  
*Lawrence Livermore National Laboratory*

**Brett Singer**  
*Lawrence Berkeley National Laboratory*

**Rajesh Singh**  
*Pacific Northwest National Laboratory*

**Michael Sohn**  
*Lawrence Berkeley National Laboratory*

**Eric Thacher**  
*University of California, Berkeley*

**Bill Thompson**  
*SLAC National Accelerator Laboratory*

**Ronald Underhill**  
*Pacific Northwest National Laboratory*

**Evan Variano**  
*University of California, Berkeley*

**Brian Viner**  
*Savannah River National Laboratory*

**Alex Vlachokostas**  
*Pacific Northwest National Laboratory*

**Nora Wang**  
*Pacific Northwest National Laboratory, now American Council for an Energy-Efficient Economy*

**Katrina Waters**  
*Pacific Northwest National Laboratory*

**David Werth**  
*Savannah River National Laboratory*

**Elizabeth Wheeler**  
*Lawrence Livermore National Laboratory*

**Annmarie Wood-Zika**  
*Lawrence Livermore National Laboratory*

**Eugene Yan**  
*Argonne National Laboratory*

**Haoran Zhao**  
*Lawrence Berkeley National Laboratory*

# Acronyms and Abbreviations

<b>1D, 2D, 3D</b>	one-, two-, three-dimensional
<b>3CLpro</b>	3 chymotrypsin-like protease
<b>ACE2</b>	angiotensin-converting enzyme 2
<b>AI</b>	artificial intelligence
<b>CARES Act</b>	Coronavirus Aid, Relief, and Economic Security Act
<b>CDC</b>	Centers for Disease Control and Prevention
<b>COVID-19</b>	Coronavirus disease 2019
<b>DARPA</b>	Defense Advanced Research Projects Agency
<b>DoD</b>	U.S. Department of Defense
<b>DOE</b>	U.S. Department of Energy
<b>EUA</b>	Emergency Use Authorization
<b>FDA</b>	U.S. Food and Drug Administration
<b>FEMA</b>	Federal Emergency Management Agency
<b>HHS</b>	U.S. Department of Health and Human Services
<b>LLMDA</b>	Lawrence Livermore Microbial Detection Array
<b>ML</b>	machine learning
<b>NIH</b>	National Institutes of Health
<b>NVBL</b>	National Virtual Biotechnology Laboratory
<b>PLpro</b>	papain-like protease
<b>PPE</b>	personal protective equipment
<b>QC</b>	quality control
<b>R&amp;D</b>	research and development
<b>RT-LAMP</b>	Reverse Transcription Loop-mediated isothermal AMPLification
<b>RT-PCR</b>	reverse transcription polymerase chain reaction
<b>SARS-CoV-2</b>	severe acute respiratory syndrome coronavirus 2
<b>STEM-EDS</b>	scanning transmission electron microscopy–energy-dispersive X-ray spectroscopy